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The failure of evidence to translate into policy and practice is one of the most common and 
disconcerting findings in health services research. Whilst many strategies have been suggested to 
facilitate translation of evidence-based research, little is known about how these strategies should be 
adapted for different types of evidence. The principal aim of the thesis is to better understand the 
factors that determine the translation of evidence from economic evaluation into healthcare policy 
and practice. 
Methods 
A literature review of the barriers and facilitators to using evidence from economic evaluations was 
conducted and mapped to the Consolidated Framework for Implementation Research (CFIR) to 
develop a framework specific for economic evaluation (CFIR-EE). Decision-makers, including 
health professionals, healthcare administrators or managers, and health researchers, were surveyed 
about the factors that determine whether and how they use evidence from economic evaluations. 
The relative importance of these factors was measured using a discrete choice experiment. Semi-
structured interviews were conducted with health economists to explore their experiences 
translating evidence from economic evaluation into healthcare policy and practice. 
Results 
The CFIR-EE highlights the multilayered interactions between the economic evaluation, individual 
decision-makers and the context in which the decision-makers work. The CFIR-EE characterises 
economic evaluations in terms of accessibility, relevance, and credibility. The discrete choice 
experiment (N=81) showed that healthcare decision-makers were willing to make trade-offs 
between these characteristics. Specifically, there were preferences amongst decision-makers for an 
economic evaluation that is good quality, specifically applicable to the healthcare context and 
communicated well by an independent researcher. High methodological rigour was valued but did 
not dominate. The views from the health economists interviewed (N=9) were consistent with the 
CFIR-EE, but also identified determinants of translation that had not previously been identified. 
Novel determinants found through the process included the importance of professionalism, the 
inconvenience of certain methods of presenting evidence in large documents, and the use of 
inappropriate or ill-defined cost-effectiveness thresholds. The importance of communication and 
engaging with stakeholders and clinical experts was a common theme for all of the health 
economists interviewed. 
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 Conclusions 
To translate evidence from economic evaluation into healthcare process it is necessary at each stage 
of the process to find the correct balance between credibility, accessibility, and relevance taking into 
account the inner and outer setting and knowledge and attitudes of the decision-makers. To 
increase the impact of economic evaluation on policy, health economists need to actively engage 
with policymakers, healthcare professionals, and the community.  
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1 OVERVIEW OF THESIS 
1.1 BACKGROUND 
With increasing concerns about health budget constraints, and an ageing population, there is 
growing pressure to reduce spending on low value healthcare interventions.1 The decisions made 
about how healthcare resources are spent have a large and direct impact on the public through 
government and private expenditure on health and the ability to access care.2, 3 The process of 
assessing the economic value of an intervention—economic evaluation—serves an important role 
in making sure the process of discerning low value healthcare interventions from high value 
interventions is evidence-based and that the impact of bias and special interests is reduced. 
The failure of evidence to translate into policy and practice is one of the most common findings in 
health services research.4 Implementation science, the study of how to narrow the research-practice 
gap, is a complex, growing and evolving field.5-7 The ultimate aim of implementation science is to 
reduce the time it takes for healthcare practice to respond to evidence and achieve a meaningful and 
significant change in clinical and services outcomes.  
There are many difficulties encountered in the translation of knowledge in a healthcare setting. 
Researchers and healthcare decision-makers have differences in incentives and norms, which can 
manifest as difficulties in communicating with each other and incompatible priorities.8, 9 The need 
for researchers, particularly at academic institutions, to publish novel and rigorous research does 
not always align for healthcare decision-makers’ pragmatic needs for making immediate decisions. 
Complexity of methods and the obscurity of academic language can make translation challenging.  
The nature of economic evaluation as a type of evidence results in unique challenges for translating 
into healthcare policy and practice. Economic evaluation is designed to improve decision-making 
within the healthcare context. However, economic evaluations include theory and language 
uncommon in healthcare practice. Translation of evidence from economic evaluations into 
healthcare practice have not been widely successful,10 and the health policy impact of economic 
evaluation remains uncertain.11, 12  
Some challenges to translating evidence into practice are specific to economic evaluation.13 Most 
healthcare professionals and managers do not have training in producing or interpreting economic 
evaluations.14, 15 Specialised terminology and statistical methods can make economic evaluations 
difficult to understand.16 The topics addressed in economic evaluations often do not meet the 
needs of healthcare professionals and policymakers.17, 18 Sometimes, the time it takes to complete an 
economic evaluation is longer than the time available to make a decision.14 Healthcare professionals 
have reported being uncertain about the methodological quality of economic evaluations14, 15, 19 and 
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have stressed that equity considerations should be included as well as evidence relating to cost-
effectiveness.14, 20  
The barriers to translating evidence from economic evaluation into healthcare practice, identified 
through the literature, were predominantly identified through two methods: (1) qualitative 
interviews or (2) surveys of health professionals and policymakers.13 Whilst insightful the two 
methods do not provide a measure of trade-off—what the decision-makers would be willing to give 
up in order to overcome the specific barriers identified. Measuring such trade-offs quantitatively 
provides a mechanism for identifying strength of preference or priorities in criteria for developing 
and communicating economic evaluations from a healthcare decision-makers perspective.  
The thesis describes multiple approaches to better understand how to get evidence from economic 
evaluations into healthcare practice. The perspectives of users (decision-makers) and producers 
(health economists) of economic evaluations were gathered. A literature review was conducted to 
identify the barriers and facilitators to using evidence from economic evaluations in healthcare 
decision-making. The findings of the review were mapped to the constructs and domains of the 
Consolidated Framework for Implementation Science (CFIR), in order to adapt the framework for 
use in understanding the translation of evidence from economic evaluations. A discrete choice 
experiment was conducted to measure the healthcare decision-makers’ relative importance of the 
barriers to using evidence from economic evaluations. Lastly, semi-structured interviews were 
conducted with health economists to explore their experiences translating evidence from economic 
evaluations into healthcare policy and practice.  
1.2 RESEARCH AIM AND CONTRIBUTION OF THESIS 
The aim of this research is to understand how to get evidence from economic evaluations into 
healthcare practice. The following objectives and related research tasks were designed in order to 
achieve the aim. 
1. Identify the barriers to using evidence from economic evaluations in healthcare 
decision-making. 
Study 1a 
Systematic identification of the barriers and facilitators to using evidence from 
economic evaluations in healthcare policy and practice. 
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2. Develop a theoretical framework for the translation of evidence from economic 
evaluation into healthcare decision-making. 
Study 1b 
Mapping of the barriers and facilitators to using evidence from economic 
evaluations onto the Consolidated Framework for Implementation Research in 
order to identify gaps, inconsistencies and emergent relations.  
3. Determine the relative importance of these barriers to healthcare decision-makers 
Study 2 
Discrete choice experiment to examine the relative importance of a range of 
barriers and facilitators of using economic evaluations in healthcare decision-
making. 
4. Understand the translation of evidence from economic evaluation from the perspective 
of health economists who produce the economic evaluations.  
Study 3 
Semi-structured interviews with health economists to learn from the experiences 
of health economists translating evidence from economic evaluation into 
healthcare policy and practice. 
 
This research has been conducted as part of the Centre for Research Excellence in Reducing 
Healthcare Associated Infections (CRE-RHAI), whose aim is to evaluate infection control 
programmes. The research outlined herein contributes to the CRE-RHAIs commitment to ensuring 
that cost-effectiveness research into infection control programmes translates into changes in health 
services.  
1.2.1 Peer reviewed publications arising directly from thesis  
Merlo G, Page K, Ratcliffe J, Halton K, Graves N. Bridging the Gap: Exploring the Barriers to 
Using Economic Evidence in Healthcare Decision-making and Strategies for Improving Uptake. 
Applied Health Economics and Health Policy. 2014. 
Merlo G, Halton K, Graves N, Ratcliffe J, Page K. Understanding The Underutilisation Of 
Evidence From Economic Evaluations In Healthcare: A Mixed Methods Design. Value Health. 
2015;18(7):A527. 
Page K, Merlo G, Ratcliffe J, Halton K, Graves N. What factors make Economic Evaluation more 
valuable as a service? Value Health. 2015;18(3):A85. 
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Merlo G, Page K, Halton K, Ratcliffe J, Graves N. Healthcare decision-maker preferences for 
economic evaluation evidence: a discrete choice experiment. Medical Decision Making Policy and 
Practice (Under review). 
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2 LITERATURE REVIEW 
The literature review describes economic evaluation (Section 2.1), the settings in which economic 
evaluation is used (Section 2.2), the barriers and facilitators to using evidence from economic 
evaluations in healthcare decision-making (Section 2.3), and the potential role of implementation 
science in understanding the translation of evidence from economic evaluation into healthcare 
policy and practice (Section 2.3). 
2.1 ECONOMIC EVALUATION 
Economic evaluation is a tool of evidence-based decision-making.21, 22 For decision-making in 
healthcare policy and practice to be evidence-based the decisions must be informed by a systematic 
approach that synthesises the available evidence. The purpose of an economic evaluation is to make 
informed decisions that recognise opportunity costs—the cost of the next best alternative that is 
forgone. Economic evaluation supports the fundamental purpose of evidence-based decision-
making by focussing on “what works”.23  
The people who produce economic evaluations—health economists*—identify, measure and value 
the inputs and outcomes of decision alternatives in order to determine which alternative provides 
the greatest value for money.24 Economic evaluation is based on the notion of marginal analysis—
informing decisions by measuring and comparing the additional benefits of an activity (the 
incremental benefit or effectiveness) to the additional cost of an activity (the incremental cost). 
Economic evaluations have been produced for a wide range of healthcare interventions—
pharmacological, surgical, public health, screening, and diagnostics.24 
The simplest type of economic evaluation is the cost analysis.24 Cost analyses identify, measure, and 
value the resources associated with interventions or diseases. Cost comparison studies are cost 
analyses of interventions, and cost of illness studies are cost analyses of diseases. Cost comparison 
studies are used when interventions have equivalent effectiveness and safety, and therefore the 
relevant aspect of the decision is the relative cost of the interventions. Cost of illness studies 
measure the economic burden of a disease and they can be useful for priority setting but less useful 
for making decisions about healthcare delivery.  
Cost consequence studies report all of the consequences of the intervention being evaluated, 
including cost and health consequences, but do not aggregate the results. The reader of the cost 
consequence study must make the judgement about whether the intervention is cost-effective. The 
advantage of the cost consequence approach is that it simplifies the evaluation, avoiding some of 
                                                     
* “Health economist” is a commonly used term for the people who produce economic evaluation, although 
not all health economists produce economic evaluations and many people who produce economic 
evaluations come from non-economic backgrounds. 
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the terminology and the assumptions required for the aggregation associated with other 
approaches.25  
For an economic evaluation to say that benefits do or do not outweigh costs, the evaluation must 
rely on a normative framework. A normative framework attempts to define what public policy 
should do. The choice of a normative framework has consequences in the methods of evaluation 
that will be used. Table 1 presents two common normative frameworks in health economics and 
the methods of economic evaluation associated with them—welfarism and extra-welfarism. 
In order to provide normative guidance for what should be considered cost-effective there needs to 
be a framework for what should be considered a good decision.  












Welfarist Cost-benefit Monetary units Multiple effects common 
to both alternatives 
Natural units (e.g. life-





Monetary units Single effect of interest, 
common to both 
alternatives 
Natural units (e.g. life-
years gained, points of 
blood pressured 
reduction) 
Cost-utility  Monetary units Single or multiple effects, 
not necessarily common 
to both alternatives 
Healthy years (typically 
measured as QALYs) 
QALY, quality-adjusted life-years 
 
Welfarism is based on two normative assumptions:26-29 (1) that the welfare of a society should be 
judged by the individuals of that society; and (2) that the welfare of a society is improved if the 
welfare of any individual in that society is improved without making anyone else worse off. The 
second assumption is sometimes relaxed to say that reallocation is still optimal if the individuals 
who benefit would still be better off after providing compensation to the individuals made worse 
off. The welfarist approach to economic evaluation is characterised by the use of cost-benefit 
analysis, where the cost of the intervention is compared to the monetary value of the benefit of the 
intervention. Monetary value of benefit is measured by obtaining individuals’ willingness to pay for 
the health gains. It is rarely possible to directly measure an individual’s willingness to pay for health 
gains because it is difficult to distinguish how much an individual values health gains (their 
willingness to pay) from their financial constraints (ability to pay).30 Contingent valuation 
techniques are often used to elicit individual’s willingness to pay by asking how they think they 
would behave given a hypothetical scenario.31  
In contrast to the welfarist approach the objective of an extra-welfarist approach to health policy is 
not to maximise welfare, but rather has a more limited objective of maximising health gains given a 
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limited health budget. The type of economic evaluation associated with extra-welfarism—cost-
effectiveness analysis—is the most common type seen in the health economics literature.32, 33 
Whereas a cost-benefit analysis measures all consequences monetarily, a cost-effectiveness analysis 
assesses the incremental cost of an intervention in relation to the incremental improvement in 
health outcomes (the effectiveness).  
Any health outcome can be used in a cost-effectiveness analysis as the measure of effectiveness, but 
a common measure of health benefit is required if the cost-effectiveness of interventions is going to 
be compared between different population groups. A quality-adjusted life-year (QALY) is often 
used in economic evaluations for this purpose. QALYs measure survival in years adjusted for 
quality of life; health consequences are adjusted by utility weights based on relative preferences for 
particular health states. Utility weights are frequently determined by healthy members of the general 
public who provide their preferences for various health states, such as blindness34 or diabetes.35 
Years living in poor health result in fewer QALYs compared with the same period of time in full 
health. Cost-effectiveness analyses that use QALYs as the measure of health benefit are sometimes 
called cost-utility analyses. Incremental change in costs and health benefits associated with the 
intervention compared with the comparator (the current standard of care). 
Cost-benefit analyses, cost-effectiveness analyses and cost-utility analyses can all either be measured 
prospectively or estimated using decision analytical modelling.36, 37 A trial based evaluation has the 
advantage of being internally valid but can lack generalisability if the costs are specific to the trial 
setting. Furthermore, a trial based economic evaluation can only include costs and health 
consequences that occur within the trial period, and the trial might not include all the relevant 
alternatives for treatment.  
Some of the limitations of trial-based designs can be addressed through the use of decision analytic 
modelling. A decision analytic model states the relevant decisions under investigation and estimates 
the likely costs and consequences associated with these decisions.38 Decision analytic models often 
use clinical trial data to define model parameters39. Decision analytic models can incorporate 
multiple sources of uncertainty to assess how responsive the findings are to variations about 
assumptions in the model.  
Cost-effectiveness analyses (including cost-utility analyses) sometimes present results in terms of 
incremental cost-effectiveness ratios (ICERs).24 The ICER is the ratio of the incremental cost to the 
incremental benefit—the difference in cost and health benefit between the intervention and the 
comparator (the current standard of care). If a new healthcare intervention has an ICER of $30,000 
per QALY, it means that there is a cost of $30,000 for every QALY the new intervention provides 
to the population.  
   
Chapter 2: Literature review  8 
 
The ICER can be visually presented on the cost-effectiveness plane (Figure 1). The axes on the 
plane represent incremental cost and incremental effectiveness compared with the current standard, 
which is located at the intersect. Interventions in the bottom-right quadrant cost less and produce 
greater health outcomes compared with the current standard of care. Conversely, interventions in 
the top-left quadrant cost more and produce worse health outcomes compared with the current 
standard of care. The top-right quadrant represents a common situation for new and effective 
technologies, where they improve health but at an increased cost. The bottom-left quadrant 
represents interventions that could save money, but with a worsening of health outcomes. As a 
society we rarely invest in such interventions or technologies that worsen health at the expense of 
reduced cost for both political and ethical reasons. However, there is a growing awareness about 
the importance of disinvestment of low value healthcare in order to gain efficiencies.40  
Figure 1 Cost-effectiveness plane24 
 
Whether interventions in the top-right and bottom-left quadrants are judged to be cost-effective 
depends on how much individuals or the health system is willing to pay per QALY; which is known 
as the cost-effectiveness threshold. The cost-effectiveness threshold represents the willingness to 
pay for a QALY gain. Interventions with ICERs below the cost-effectiveness threshold are 
considered cost-effective.  
Cost-effectiveness thresholds have often been based on historical decisions. There is no defined 
threshold within Australia, although the PBAC considers drugs below the threshold of 
$30,000/QALY to be cost-effectiveness and above the threshold of $70,000/QALY to not be cost-
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effective.41 Several authors have argued that the threshold should be lower than what is commonly 
used in practice in order to accurately represent the opportunity cost of the decision.42-44 Under the 
threshold approach it is the change in health outcomes that are relevant, but it has been found that 
people have a greater willingness to pay per QALY for more severe health states.45 The threshold 
assumes that a QALY gained at a cost of $30,000 is the equivalent of gaining $30,000 and losing a 
QALY. However, this is rarely reflected in practice because of loss aversion (not wanting to lose 
services that are already provided), public perceptions and resistance to change. 
Methods of exploring uncertainty within economic evaluations include sensitivity analysis, scenario 
analysis, and probabilistic sensitivity analysis.24, 38 Sensitivity analysis involves varying model inputs 
to see how robust the cost-effectiveness estimate is to the changing values. Scenario analysis 
involves varying overarching assumptions—such as the timeframe or assumptions about models of 
care—to assess uncertainty in the structure of the decision analytic model. Probabilistic sensitivity 
analysis is a method used in modelled economic evaluations where the values of the parameters in 
the model are chosen probabilistically; a process that is repeated in order to get a random sample.  
The results of a probabilistic sensitivity analysis can be presented as a scatterplot (see Figure 2). 
Iterations from the probabilistic sensitivity analysis are plotted on the cost-effectiveness plane. The 
ellipse represents the 95% confidence interval—95% of the iterations are within the ellipse. The 
doted diagonal line represents the cost-effectiveness threshold. In this example the cost-
effectiveness threshold represents a willingness to pay of $20,000 per QALY. All values below the 
threshold are considered cost-effective. 
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Figure 2 Example uncertainty analysis scatterplots46 
 
The results from a probabilistic sensitivity analysis can also be presented graphically as a cost-
effectiveness acceptability curve (see Figure 3). The cost-effectiveness acceptability curve is a visual 
display of the probability that an intervention is cost-effective at each of the cost-effectiveness 
thresholds. The graph presents the probability that the intervention is cost-effectiveness at each 
willingness to pay per QALY. In this example the drug has close to zero probability of being cost-
effective at a willingness to pay of $2,000/QALY and a close to 100% probability of being cost-
effective at a willingness to pay of $20,000. This example demonstrates the importance as well as 
the subjectivity of the cost-effectiveness threshold.  
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Figure 3 Example cost-effectiveness acceptability curve47 
 
Cost-effectiveness needs to be balanced with other decision criteria, such as equity and 
accessibility.24 If an intervention is cost-effective that does not mean that the intervention upholds 
the principles of equity. Moreover, cost-effectiveness is often balanced with other expectations that 
people have for the healthcare system in terms of the ability to access care and the nature of the 
care. One method of balancing the criteria is to incorporate all the decision-making criteria into the 
cost-effectiveness or cost-benefit estimate. Another method to balance competition decision 
criteria is multiple-criteria decision analysis (MCDA), which is a mathematical approach for making 
a decision between a set of alternatives based on criteria that are weighted to reflect the preferences 
of the decision-maker or population.48-52  
2.2 SETTINGS FOR USE OF ECONOMIC EVALUATION 
Organisations that regularly use economic evaluations for decision-making often have established 
processes for translating evidence from economic evaluations into practice. Australian 
reimbursement agencies that use economic evaluations for decision-making include the 
Pharmaceutical Benefits Advisory Committee (PBAC) and the Medical Services Advisory 
Committee (MSAC).53 The agencies, as well as their subcommittees make recommendations to the 
Minster for Health about whether pharmaceuticals and medical technologies should be funded 
nationally.54 The recommendations are made based on the cost-effectiveness of the health 
technologies, so pharmaceutical and medical device companies prepare submissions defending the 
cost-effectiveness of their products. The submissions follow standard templates, which include 
instructions for analysing the cost-effectiveness of the product compared with the current standard 
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of practice and instructions for how to present the results of the evaluation. The Committees have 
their own evaluators (including health economists) to review and decide whether it is appropriate to 
fund the intervention. Sometimes the process is used to negotiate price or establish a risk-sharing 
agreement with the companies. For the organisations, economic evaluations are structurally 
supported and integrated into the decision-making process at the highest level, so there is minimal 
need to have additional strategies to ensure that economic evaluation is used in the decision-making 
process.  
At the state level there are health technology assessment (HTA) agencies such as the Queensland 
Policy and Advisory Committee for New Technology (QPACT). HTA is the process of identifying 
new medical technologies, evaluating their key dimensions and effects, and monitoring their 
diffusion into healthcare practice.55 Cost-effectiveness is only one of the criteria used for evaluation 
within heath technology assessment, alongside other criteria such as safety, efficacy, and quality and 
also social impact on equity or innovation.55  
There are international counterparts to the PBAC and MSAC and the state-based HTA agencies.56-
58 In the UK there is the National Institute for Health and Care Excellence (NICE),57, 59, 60 which 
differs from the PBAC in the breadth of responsibilities and the evaluation practices. Unlike the 
PBAC and MSAC, NICE is not limited to assessing pharmaceutical and medical device, but 
includes all health technologies and health services within the UK’s National Health Service (NHS). 
In terms of evaluation practice, NICE differs from the PBAC in the proportion of submissions 
accepted, the willingness to negotiate price, and how study design impacts the decision.61 However, 
like the PBAC, the ICER of evaluated interventions has a significant impact on NICE decision-
making.62 Nevertheless, only about half of the health technologies that NICE have recommended 
had an associated ICER.63 
Other organisations that use economic evaluation for healthcare decision-making—sometimes 
called HTA agencies—include the Canadian Agency for Drugs and Technologies in Health 
(CADTH),61 Germany’s Institute for Quality and Efficiency in Health Care (IQWiG),64 the Swedish 
Council on Technology Assessment (SBU),65 New Zealand Health Technology Assessment 
(NZHTA),57, 66 and Thailand’s Health Intervention and Technology Assessment Program 
(HITAP).67 Economic evaluations are also used for hospital formulary decision-making—where 
hospitals decide which pharmaceuticals they are going to stock and provide to patients.68 
Furthermore, economic evaluations sometimes form part of clinical practice guidelines,69 including 
National Health and Medical Research Council (NHMRC) guidelines in Australia.70  
Even with the existence of HTA agencies, the proportion of healthcare interventions that are 
validated and based on sound scientific evidence—let alone cost-effectiveness evidence—is small.71 
Use of economic evaluation is mostly limited to decisions at the national level.15, 17, 18, 59, 64, 72-75 
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Decision-making at the local level tends to be made based on current standards, customs and what 
has been funded in the past.17, 76, 77 Other influencers on healthcare decision-making include the 
knowledge and experience of the healthcare professional, the characteristics of the patient, financial 
incentives, fear of malpractice litigation, and awareness of costs.78  
2.3 BARRIERS AND FACILITATORS TO USING EVIDENCE FROM 
ECONOMIC EVALUATION 
The following section reviews the barriers and facilitators to using evidence from economic 
evaluation using the Accessibility-Acceptability Framework.79 The Accessibility-Acceptability 
Framework was developed specifically for economic evaluation. According to the framework the 
use of evidence from economic evaluation in healthcare decision-making depends on whether the 
economic evaluation is accessible and acceptable. The accessibility of evidence from economic 
evaluations depends on research being able to be obtained and understood in a timely manner. 
Acceptability depends of scientific acceptability (“is it accurate?”) and ethical acceptability (“is it the 
right thing to do?”). The literature review that characterises the barriers ad facilitators using the 
Accessibility-Acceptability Framework is used to define the attributes of the discrete choice 
experiment in Section 1. 
The following section describes the findings of a review published as part of the thesis (See 
Appendix A).13 The review investigated the barriers and facilitators to using evidence from 
economic evaluation using the Accessibility-Acceptability Framework, which was developed 
specifically for the translation of evidence from economic evaluation into healthcare policy and 
practice. 
2.3.1 Accessibility 
An economic evaluation is accessible if the policymaker has timely access to relevant research that is 
understandable.79 Identified barriers to accessibility include the absence of relevant available 
economic evaluations for decision-makers,14, 15, 73, 75, 80-87 the time and cost required to conduct 
economic evaluations,14, 19, 87-90 decision-makers’ lack of time to evaluate research,8, 17, 90, 91 difficulties 
translating economic evaluations into different contexts,18, 82, 87, 92 and poor awareness of current 
evaluations.14, 15, 17, 18, 80, 93 Economic evaluation is rarely part of academic criteria in graduate 
medical education.94 Barriers to understanding the evidence include poor communication from 
health economists (including overuse of jargon),15, 16, 90 complexity of economic evaluation design,16, 
19, 82, 87 confusion with methods of presenting results;19 excessive variation in economic evaluation 
methodologies and presentation,14, 16, 80 and the lack of economic evaluation expertise amongst 
decision-makers.8, 14-17, 19, 80, 90, 91, 93, 95-102  
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Healthcare decision-makers, including physicians, pharmacists, hospital administrators, and 
politicians have recommended that health economists should simplify language and analysis 
methods,16, 82, 90, 101, 102 and use standard brief report formats for presenting economic evaluations.8, 
14-16, 103Some decision-makers favour the presentation of results in a disaggregated format (i.e., cost 
consequence analysis).82, 104 Having decision-makers involved who have previous experience using 
cost-effectiveness analysis in decision-making helps manage the complexity of using the research 
for decision-making.19  
Sullivan et al (2015)105 reviewed guidelines and templates for presenting results from economic 
evaluations. None of the reporting templates specifically targeted policymakers or non-technical 
audiences. The guidelines recommend economic evaluations to have templates for presenting well-
cited tables of data sources, transparent model descriptions and diagrams, disaggregated results, and 
tabular and graphical displays of sensitivity analysis. Few of the guidelines provide any advice for 
presenting information to non-economists, but suggestions included minimising excessive jargon 
and providing a glossary of economic terminology. The review, however, provided several 
suggestions for presenting economic evaluations to non-economists, including (1) specifying the 
differences between the societal and healthcare payer perspective, (2) using adequate time horizons, 
(3) specifying how outcomes such as QALYs and life-years relate to component clinical outcomes, 
and (4) describing how sensitivity analysis methods were chosen. The authors concluded that best 
practice and educational resources for communicating results from economic evaluations needs to 
be further explored, noting the difficulty in presenting results in a way that is both simple and 
valid.9, 105 Policymakers’ preferences for being able to deconstruct analyses and for understanding 
how the results of economic evaluations apply at a practical level do not appear to be reflected in 
published guidelines for how to present results from economic evaluations.105 Therefore, there 
exists considerable scope for further work in the area. 
Hoffmann et al.18 conducted focus group research with decision-makers from UK health 
authorities to evaluate whether they found the NHS Economic Evaluation Database facilitated the 
accessibility of evidence from economic evaluations. The NHS Economic Evaluation Database 
contains structured abstracts of published economic evaluations, and was designed to overcome 
accessibility barriers. The decision-makers in the focus group reacted positively to the NHS EED, 
saying that it would aid in the identification of relevant research. The decision-makers identified 
limitations of the NHS EED including the lack of generalisability the evaluations in the database 
conducted outside of the UK and the inability to evaluate the quality of the evidence from the 
economic evaluation given the compressed format of the NHS EED study summaries.  
Thurston et al.106 assessed different summary formats for presenting results from an economic 
evaluation, using a survey of healthcare decision-makers in the UK who were users of the NHS 
Economic Evaluation Database. The healthcare decision-makers (n=84), who preferred a 
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combination of summary formats with a short summary plus a more detailed structured abstract. 
Decision-makers with economics training preferred a structured abstract that was more detailed 
compared with the favoured structured abstract of the other decision-makers. The decision-makers 
seemed to have two needs for the evidence summaries. First, the majority wanted a format that can 
be rapidly scanned and compared; and second they wanted a more detailed version that they could 
review for studies they considered relevant. The study highlights the importance of providing 
multiple formats when presenting information for different purposes to different audiences. 
Decision-makers from multiple health contexts suggested training as a method of overcoming the 
barriers to using economic evaluations,8, 14-16, 82 although there are no studies that have assessed the 
impact of training on decision-makers’ attitudes and knowledge of economic evaluation. Training 
material was provided in the pilot study conducted by Claxton et al.107 to investigate the potential 
for decision analysis and value for information analysis to inform the prioritisation process of the 
NHS’s HTA programme. Some members of the HTA programme said that the training material 
was insufficiently detailed; while others said that the material was too detailed and technical; 
highlighting the need to tailor the training and dissemination of information to different groups of 
people. 
All told, the accessibility of an economic evaluation is multifaceted and whilst there is research to 
examine its various components of timeliness, understanding and relevance, the solutions to 
improving accessibility remain largely poorly understood. 
2.3.2 Acceptability 
Just because healthcare decision-makers can use evidence from economic evaluations does not 
mean that they would want to. A decision-maker might not want to use an economic evaluation 
because it lacks scientific, institutional, or ethical acceptability.79 
2.3.2.1 Scientific acceptability 
Evidence from economic evaluation is scientifically acceptable if the methods are valid and the results 
are unbiased.79 Decision-makers have reported concerns about some of the methods used in 
economic evaluations. Such methodological issues include poor quality of research informing 
economic evaluations,16, 18, 19, 87, 89, 93, 99 use of QALYs to measure health effects,14, 16, 100, 108 methods 
used to estimate indirect and overhead costs,87, 109 insufficient description of modelling 
assumptions,14, 15, 18, 94 lack of description of the quality of the data used,89 results not representing 
true uncertainty,19 and the appropriateness of the cost-effectiveness threshold.14, 19, 81, 82, 87  
Decision-makers regard conflicts of interest as a barrier to using economic evaluations.14, 16, 82, 91, 100, 
110 Industry funded economic evaluations are prevalent in the academic literature,111 raising 
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concerns that methods are being selected that introduce bias, either in the model design or the 
selection of parameters. Economic evaluations, like other research, are susceptible to publication 
bias, as economic evaluations with positive findings are more likely to be published.112  
Another aspect of scientific acceptability is whether economic evaluations are consistent with 
welfare economics and economic principles more generally. Although the consistency of economic 
evaluation with welfare economics has been debated in the academic literature,26, 113 it was not a 
concern to the decision-makers surveyed or interviewed about the barriers to using economic 
evaluations.14, 72  
2.3.2.2 Institutional acceptability 
Evidence from economic evaluation is institutionally acceptable when it meets the institutional 
needs of the decision-maker. Policymakers and healthcare practitioners have recommended that 
health economists need to demonstrate a better understanding of the decision-making process in 
the healthcare system, particularly with regard to the difficulties in transferring resources between 
sectors and adjusting budgets for new therapies.14, 15, 76, 82, 87, 91, 93, 114 The limited transferability of 
economic evaluations from other contexts is often identified as a challenge.91, 100 Healthcare 
professionals and policymakers have found that published economic evaluations often address a 
narrow scope of research questions, and typically ignore concerns that decision-makers often face, 
including human resource management decisions.17, 18 Conversely, economic evaluations of 
nationwide programs can be too broad to be of relevance to individual hospitals with specific 
requirements and timeframes.14 Following guidance from an economic evaluation might not be 
institutionally acceptable if it advocates disinvestment of an established technology,8, 14, 40, 115, 116 or if 
the findings run contra to the short-term focus of decision-makers.117, 118 The relevance of an 
economic evaluation can be limited by which pharmaceuticals and medical devices have regulatory 
approval or approval from reimbursement, and which are recommended in clinical practice 
guidelines.114  
Decision-makers have found that potential economic benefits of interventions highlighted in 
economic evaluations are not being realised in practice.14, 15, 82 The lack of benefits in practice might 
be because of institutional limitations—if individuals in each ward of a hospital are only responsible 
for the budget of their ward then economic benefits accrued to another ward would be considered 
relevant for the economic evaluation but less relevant to the individuals within the original ward. 
Alternatively, if patient behaviour, response to treatment, or any other assumption is not as 
predicted then that can result in economic benefits highlighted in economic evaluations not being 
realised in practice.  
Approaches that that have been suggested to improve the institutional acceptability of economic 
evaluations include (1) making economic evaluations more relevant to the decision-making 
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context,14, 73(2) allowing flexibility in decision-making budgets to adopt recommended changes,15 (3) 
incorporating budget and resource reallocation constraints in models,119, 120 (4) making economic 
evaluations more sensitive to questions that healthcare decision-makers need answers to,14, 73 (5) 
involving all stakeholders in the economic evaluation process,73 and (6) demonstrating direct 
benefits to the administrator or department concerned.90 Official requirement to demonstrate the 
cost-effectiveness of interventions for third party funding or reimbursement also promotes the 
development and use of economic evaluations.121 The impact of economic evaluations on policy is 
often related to the level of cooperation between researchers and policymakers,14, 110 which explains 
why the economic evaluations most successful in influencing policy are those that are 
commissioned by the policymakers themselves.122-124 
2.3.2.3 Ethical acceptability 
Ethical acceptability refers to whether the decision-maker and the wider community consider the 
methods, findings or recommendations from the research to be ethically “right”. A concern that 
has been raised by decision-makers is that economic evaluations rarely consider or report the 
impact that an intervention has on equity.14, 16, 19, 20, 89, 115, 125 There are many ways to address equity 
concerns but the methods often depend on the equity criteria of the decision-makers.113 If 
policymakers want to know the impact of a policy on equality in health outcomes or access to 
services then health economists should try to find an effective and meaningful way to present the 
information. 
Explicit rationing itself is ethically unacceptable to some decision-makers126. There can be conflict 
between the individual ethic of the doctor-patient relationship and the population ethic of cost-
effectiveness.14, 109 The doctor-patient relationship focusses on the effectiveness and safety of 
treatment, with less concern about the cost of treatment. But economic evaluations take a social or 
administrative perspective, where between-patient trade-offs in the use of healthcare resources need 
to be accounted for, which can result in economic evaluation becoming synonymous with cost 
cutting in the eyes of doctors.14, 73, 86 To address the concern of cost-cutting, economic evaluations 
should highlight to doctors and other health professionals the benefits accrued to all their patients 
as opposed to any one patient. One study114 found that HTA agencies largely ignored divergent 
views about economic evaluation, which most likely impacts the acceptability of the findings to a 
range of stakeholders.  
2.3.3 Accessibility and acceptability trade-offs 
The constructs of accessibility and acceptability provide a framework to evaluate strategies to 
increase the usefulness of evidence from economic evaluations or increase the impact that the 
evidence has on policy. Strategies to increase usefulness of impact can have different effects on 
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each of components of accessibility and acceptability. The nature of the interactions have not been 
assessed empirically, but some interactions can be speculated (Table 1). 
Such interactions can be trade-offs. Sophisticated statistical techniques might improve scientific 
acceptability but make the research less accessible due to increased time to conduct analysis and 
difficulty in understanding results. Rapid evaluation methods sacrifice scientific acceptability to 
improve accessibility.49, 127 Decision-makers might find it easier to understand disaggregated results 
of economic evaluations rather than, say, an incremental cost-effectiveness ratio, but the 
disaggregated approach provides less support for a scientifically rigorous decision. Industry funding 
can have a negative impact on perceptions of scientific acceptability, but without industry funding 
many economic evaluations would not be conducted, limiting accessibility. Involving community 
members in healthcare priority decisions might improve community attitudes to economic 
evaluation and healthcare rationing, but their recommendations might not sit well with institutional 
powerbrokers. Incorporating budget and equity constraints into an economic evaluation might 
improve institutional and ethical acceptability but also takes time, adds complexity, and opens the 
door for criticism of methods.  
Writing well improves understanding, but at a cost.128 It takes time to write clearly and 
comprehensively. Writing well requires experience, thoughtfulness, and repeated edits. Technical 
language is a barrier to understanding for non-specialists, but researchers need to demonstrate their 
understanding of technical language to gain academic credibility.  
Decision-makers sometimes like to see economic evaluations include decision making criteria other 
than cost effectiveness, such as budget impact, resource constraints and equity impact. However, 
including decision-making criteria other than cost-effectiveness contributes to the complexity of the 
economic evaluation. Each decision-making criterion introduces new ideas that the reader has to 
grasp. Each demands knowledge and effort from the researcher to be calculated credibly.129, 130  
If cost-effectiveness, budget impact, resource constraints, and equity impact are all reported, 
another level of complexity is introduced because competing criteria need to be weighed up to 
make a decision. MCDA can be used to make the weighing up of competing criteria explicit. An 
MCDA instrument allows for the trade-off between criteria in a way that facilitates the rank 
ordering of a set of interventions.131 But MCDA introduces more ideas to be understood and it 
requires time to develop such a decision tool. 
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Table 1 Potential accessibility and acceptability interactions 
 Accessibility Acceptability 
Strategy Availability Understanding Scientific Institutional Ethical 
Rapid evaluation techniques 
      
Use plain language 
      
Disaggregated presentation of results 
(cost consequences analysis)      
Complex modelling techniques to 
minimise bias      
Conducting economic evaluations 
with industry funding      
Conducting economic evaluations 
independent from industry funding      
Clearly stating assumptions and data 
sources      
Incorporating budget and resource 
reallocation constraints       
Involving community members in 
healthcare priority decisions      
MCDA to incorporate equity 
concerns      
MCDA, multiple-criteria decision analysis 
The upwards arrows indicate that the strategies in the left column have the potential to increase or improve the subcategories of 
accessibility or acceptability in the top row. The downwards arrows indicate that the strategies have the potential to decrease or diminish 
the accessibility or acceptability subcategories 
 
The Accessibility-Acceptability Framework was developed specifically to characterise the barriers 
and facilitators to translating evidence from economic evaluation into healthcare practice. The 
Accessibility-Acceptability Framework focuses on the characteristics of the economic evaluation 
rather than the nature of the decision-makers, the context of the decision, or the process of 
translating evidence into practice. The framework was based on findings from qualitative interviews 
and surveys of a variety of healthcare decision-makers. Due to the evidence source, any 
determinants that are not identified in the qualitative studies are not part of the Accessibility-
Acceptability Framework. 
There are advantages and disadvantages to using a general implementation framework rather than 
the economic-evaluation specific Accessibility-Acceptability Framework. The primary disadvantage 
of using a general implementation framework is that it is less specifically relevant for economic 
evaluation and might use terminology that would not usually be used when discussing the 
translation of evidence from economic evaluation into healthcare policy and practice. The 
advantages of using a general implementation framework—as will be used for Studies 2 and 4—is 
that it (1) facilitates identification of determinants of translation not already identified in the current 
literature; (2) allows comparison with getting other innovations into healthcare policy and practice; 
and (3) discerns characteristics relevant to the economic evaluation that determine translation from 
characteristics of the decision-makers and the decision-making context. 
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To that end, it is worthwhile to consider implementation more broadly as a field of study. The 
following section describes frameworks and strategies that have been developed for implementation 
of research findings into practice more generally, with the aim of providing a richer understanding 
of all of the potential factors at play in the translation process. 
2.4 IMPLEMENTATION SCIENCE 
The process of getting evidence—such as evidence from economic evaluations—into healthcare 
practice is slow and high quality evidence is not consistently applied across healthcare practices, 
resulting in inefficient use of healthcare resources.132 It has been estimated that 85% of research is 
wasted133 and there is a research-to-practice time delay of 17 years.134 Gaps between what is 
recommended and what physicians do and patients receive is common.135, 136 One study of the 
knowledge of a public health workforce in the USA found that all the topics assessed, economic 
evaluation had the greatest knowledge gap.137 Research is needed to understand the reasons for 
gaps in clinical practice and to identify interventions to address them.138, 139 The study of getting 
evidence into practice is called implementation science.138, 140-142 Implementation science has 
emerged from multiple fields using different terminology, frameworks and strategies.  
Implementation science provides frameworks to understand the challenges to getting evidence 
from economic evaluation into healthcare practice, and provide strategies to overcome those 
challenges.143 One of the aims of implementation science is to reduce waste in research, so that 
useful research is undertaken and the findings from the research inform decision-making, which is 
commensurate with the ultimate goals of economic evaluations. 
The simplest approach to getting evidence into practice is diffusion and dissemination. Diffusion is 
the passive spread of information to an audience and dissemination is the active process of 
spreading a message to defined target groups.144 Under the traditional academic model the 
researcher disseminates their finding through publications in academic journals and presentations at 
conferences. If the research is high quality, and the findings are relevant, then word will diffuse to 
practitioners who will change their behaviour in response to the research. Dissemination methods 
depend on the audience and how that audience uses information to make decisions. Different target 
audiences have different needs for acquiring and interpreting information. Moreover, there are 
many norms and conventions within the academic system, which mean that some types of research 
and evidence are disseminated more frequently and successfully than others. 
Implementation aims to reduce or eliminate the barriers to the translation of evidence and facilitate 
behavioural change.144 There are multiple theoretical frameworks for implementation140, 145-148 and a 
large body of empirical evidence looking at specific implementation interventions.149-157 Some 
implementation frameworks are specific to evidence from research; others are broader and relevant 
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for any innovation where implementation would require some change in the behaviour of 
individuals or organisations.  
Several trials have been conducted to evaluate the effectiveness of individual implementation 
strategies. There is strong evidence for educational outreach,158-161 including: practice visits by 
educators, the provision of promotional material, and subsequent reminders or educational follow-
up;158 educational outreach by pharmacists;159 healthcare visits from outside the organisation.160 
There is moderate evidence for audit and feedback,158-165 where the change in practice is monitored 
to inform individuals and managers. There is also moderate evidence for reminders,120, 121, 128, 129161 
including verbal reminders, reminders on paper or digital reminders. There is also moderate 
evidence for multifaceted interventions,161 where multiple implementation strategies are 
concurrently implemented. There is mixed evidence for other implementation strategies including 
mailed dissemination,121, 127-129 computerised decision support systems,158, 163, 164, 166 educational 
meetings,159, 160, 165, 167 continuing education,120, 127, 129 and opinion leaders.158, 160, 162  
Tailored implementation interventions are designed to meet specific determinants of practice within 
the relevant context.150 A tailored intervention is planned following an assessment of the barriers 
and facilitators—the determinants—to changing practice. The theory behind the tailored approach 
is that efforts to change professional practice will have a lower likelihood of success if the 
determinants of current practice are not taken into account. Methods used to identify determinants 
include: brainstorming, interviews, or focus groups of health professionals, and questionnaires.149, 
168 Commonly, interviews with implementation practitioners or health professionals are conducted 
to identify strategies to strategies to address the determinants of practice.154, 173, 174 Tailored 
implementation interventions have been developed for quality and safety improvements and 
guideline implementation,135, 169-171 but there have been no tailored implementation interventions 
developed specifically for economic evaluations.150 The effectiveness of tailored implementation 
strategies are variable, but tend to be small to moderate.150 
2.4.1 Implementation frameworks 
Implementation frameworks bring together concepts and provide structure for research into 
implementation and research utilisation.140, 142, 145 Many implementation frameworks have been 
developed within disciplines, resulting in a variety of terminology and classification concepts.145 
Some frameworks focus on changes at the level of the individual professional, while others focus 
on changes at the organizational or social level.172  
Different types of implementation frameworks will be relevant to different aspects of 
understanding, addressing, and evaluating the research practice gap for economic evaluation. There 
are five broad types of models (Table 2). Process models aim to understand the stages that would 
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be required to translate research, such as an economic evaluation, into healthcare practice.173 
Determinant frameworks aim to understand why evidence is or is not used, often using context 
domains to characterise the determinants.173 Determinant frameworks are often informed by classic 
theories of individual and organisational behaviour and decision-making from outside of the field 
of implementation research—such as the Theory of Diffusion174—and theories developed to 
understand implementation—such as the Normalization Process Theory.147 valuation frameworks 
can be used to structure evaluations of implementation programmes, such as strategies to get 
evidence from economic evaluations into healthcare practice.173  
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Table 2 Five types of implementation frameworks (adapted from Nilsen 2015173) 
Category Description Examples 
Process models Specify the steps of the process of translating research into practice 
Model by Huberman,175 model by Landry et al.,176 model by Davies et al.,177 model by Majdzadeh et 
al.,178 the CIHR Model of Knowledge Translation,179 the K2A Framework,180 the Stetler Model,181 the 
ACE Star Model of Knowledge Transformation,182 the Knowledge-to-Action Model,132 the Iowa 
Model,183, 184 the Ottawa Model,185 model by Grol and Wensing,186 model by Pronovost et al.,187 the 
Quality Implementation Framework188 
Determinant framework 
Specify the factors that act as barriers or facilitators and 
strategies that can be used to influence implementation 
outcomes. 
PARIHS,141, 181 Active Implementation Frameworks,189, 190 Understanding-User-Context 
Framework,191 Conceptual Model,192 framework by Grol et al.,135 framework by Cochrane et al.,7 
framework by Nutley et al.,193 Ecological Framework by Durlak and DuPre,194 CFIR,140 framework by 
Gurses et al.,195 framework by Ferlie and Shortell,191 Theoretical Domains Framework196 
Classic theories Theories originating outside of implementation research 
Theory of Diffusion,174 social cognitive theories, theories concerning cognitive processes and 
decision-making, social networks theories, social capital theories, communities of practice, 
professional theories, organizational theories 
Implementation theories Theories developed within implementation research to understand aspects of implementation 
Implementation Climate,197 Absorptive Capacity,198 Organizational Readiness,199 COM-B,200 
Normalization Process Theory147 
Evaluation frameworks Specify aspects of implementation that can be evaluated to determine implementation success RE-AIM,
201 PRECEDE-PROCEED,202 framework by Proctor et al.203 
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The Consolidated Framework for Implementation Research (CFIR) is a widely cited and rigorously 
developed determinants framework for implementation.204 CFIR was developed through a process 
of consolidating earlier published literature, including nineteen previously developed frameworks 
such as the Greenhalgh 2004 model,205 the PARiHS framework,206 and the Ottawa Model of 
Research Use.207 Common themes were organised into the five CFIR domains of intervention 
characteristics, outer setting, inner setting, characteristics of the individuals involved, and the 
process of implementation (Figure 4). Each domain is characterised by a set of constructs—for 
instance the inner setting domain is characterised by four constructs (structural characteristics, 
networking and communication, culture, and implementation climate).  
Figure 4 Domains and constructs within the CFIR Research140 
 
CFIR, Consolidated Framework for Implementation Research 
CFIR was designed for innovations such as changes in clinical practice or new technologies, rather 
than types of evidence. Chapter 0 uses the adapted CFIR for framework analysis of interviews with 
health economists. 
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2.5  SUMMARY OF EVIDENCE GAPS 
There is a strong theoretical rationale for the use of economic evaluation in healthcare decision-
making. Empirically there is a positive perception amongst healthcare decision-makers about the 
value of economic evaluation for making evidence-based decisions based on cost-effectiveness. 
However, outside the restricted scope of HTA agencies, there is still limited use of economic 
evaluation, which leads to both the sub-optimal use of healthcare resources and ultimately poorer 
patient outcomes. 
Implementation research is an emerging discipline. Therefore, there has been limited focus on the 
translation of evidence from economic evaluation into healthcare practice. There are specific 
challenges that need to be addressed when translating evidence from economic evaluation into 
healthcare practice. Economic evaluations are specific to the decision-making context that they are 
designed for, which can lead to problems with adaptation to different clinical contexts. Economic 
evaluations use language and methods that are unfamiliar to most health professionals and 
policymakers. Furthermore, the population focus of economic evaluations will sometimes not align 
with the individual patient focus of healthcare practice. There is therefore a need of a specific 
tailored framework for the translation of evidence from economic evaluation.  
There has been a no attempt to consolidate the research into the barriers and facilitators to using 
evidence from economic evaluations into existing implementation frameworks such as the CFIR. 
Chapter 1 presents an adaptation of CFIR for the transition of evidence from economic 
evaluations into healthcare policy and practice (CFIR-EE). The adaptation is achieved by mapping 
the findings of a systematic review of the barriers and facilitators to using evidence from economic 
evaluations in healthcare policy and practice to the domains of CFIR. The CFIR-EE characterises 
the determinants of the translation. The CFIR-EE brings together concepts and provides structure 
to the study of the translation of evidence from economic evaluations. 
The factors that prevent or encourage decision-makers using evidence from economic evaluations 
have been identified, but the relative importance of these factors to decision-makers is uncertain. 
Without a gauge for relative importance one cannot determine whether sacrificing acceptability for 
accessibility is worthwhile. Relative importance is likely to depend on the nature of the decision and 
decision-makers. Trade-offs are inherent in decision-making and that is no different for economic 
evaluations. Whilst decision-makers can easily state the absolute importance of a multitude of 
factors for economic evidence, in reality when faced with such a decision they make trade-offs and 
sacrifice some element of the decision for another. The relative preference for the attributes of an 
economic evaluation have not captured by any previous research and is essential for better 
understanding what aspects of the evidence health economists should focus their efforts on in the 
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production of such evidence. Chapter 1 details a study of decision-makers’ preferences for 
economic evaluations using discrete choice methodology. 
All of the published studies researching the barriers and facilitators to using evidence from 
economic evaluation in healthcare decision-making have involved interviews with users of 
economic evaluations rather than the health economists. To develop a prescriptive framework the 
current body of qualitative data from users of economic evaluation needs to be consolidated with 
qualitative data from the experiences of health economists trying to get their research into 
healthcare practice. Chapter 5 describes the results from a series of in-depth interviews to identify 
these strategies. Health economists from Australia and the UK were asked about their experiences 
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3 ADAPTATION OF CFIR FOR TRANSLATION OF 
EVIDENCE FROM ECONOMIC EVALUATION 
INTO HEALTHCARE POLICY AND PRACTICE 
(CFIR-EE) 
3.1 INTRODUCTION 
This chapter presents the development of the CFIR-EE (Figure 5) for the translation of evidence 
from economic evaluation into healthcare policy and practice. CFIR is a highly cited theoretical 
framework that characterises the factors that determine implementation (see Section 2.4.1). CFIR 
was designed for innovations such as changes in clinical practice or new technologies, rather than 
types of evidence.  
Figure 5 Domains and constructs within CFIR  
 
CFIR, Consolidated Framework for Implementation Research 
 
The review used the Accessibility-Acceptability Framework discussed in Section 2.3, which had 
been developed specifically for economic evaluation.79 Under the Accessibility-Acceptability 
Framework evidence from economic evaluation will be used in healthcare decision-making only if it 
is accessible and acceptable. The advantage of adapting a general implementation framework, such 
as the CFIR, rather than using the Accessibility-Acceptability Framework are that the adapted CFIR 
(1) facilitates identification of factors not already identified in the current literature; (2) allows 
comparison with getting other innovations into healthcare policy and practice; and (3) discerns 
characteristics relevant to the economic evaluation that determine translation from characteristics 
of the decision-makers and the decision-making context. 
3.2 METHODS 
A systematic search strategy was used to identify studies that investigated the translation of 
evidence from economic evaluation in healthcare decision-making. A literature search was 
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conducted in EMBASE (1947 to 2016) using a combination of economic (e.g., “economics”, 
“cost”, “pharmacoeconomics”) and decision-making (e.g., “policy”, “priority”, decision”) terms 
(Table 3). Articles were included if they were (1) in English; (2) published as a full article in a peer 
reviewed journal; and (3) reported original research (not a systematic or literature review) of 
healthcare decision-makers’ attitudes using evidence from economic evaluations. The abstracts of 
the identified papers were screened for eligibility. Complete versions of all articles that met the 
eligibility criteria were retrieved. The included articles were reviewed to identify barriers and 
facilitators to using evidence from economic evaluations in healthcare policy and practice. 
Each CFIR construct and domain was defined in terms of how it related to economic evaluation as 
an innovation. Where there was no available evidence specifically concerning economic evidence 
the construct is discussed in broader evidence terms. Barriers and facilitators identified in the 
included studies were mapped across the five CFIR domains and to the constructs within each 
domain. Gaps, inconsistencies and emergent relations were identified through the mapping process. 
There were four objectives to the mapping:  
1. Identify gaps where there is no evidence of barriers or facilitators relating to the CFIR 
constructs or domains. 
2. Identify barriers and facilitators that do not fit within the CFIR constructs or domains. 
3. Identify terminology in the terms used to define the CFIR constructs and domains that 
could lead to confusion or inconsistency when applied to economic evaluation as an 
innovation. 
4. Observe emergent relationships between the CFIR constructs and domains when applied 
to economic evaluation as an innovation. 
Table 3 Literature review search strategy (July 2016) 
No. Query Results
#1 cost*:ti 123886 
#2 economic*:ti 46823 
#3 polic*:ti 54675 
#4 priorit*:ti 13708 
#5 decision*:ti 57784 
#6 cost*:ti OR economic*:ti 167736 
#7 polic*:ti OR priorit*:ti OR decision*:ti 124909 
#8 (cost*:ti OR economic*:ti) AND (polic*:ti OR priorit*:ti OR decision*:ti) 4023 
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3.3 RESULTS 
3.3.1 Included studies 
A total of 4023 articles were identified through the initial EMBASE search and an additional 83 
articles were identified through bibliographic records (Figure 6). After initial screening 3370 
citations were excluded. Full text articles were assessed for 211 articles, 112 of which were 
subsequently excluded. A total of 49 studies met eligibility criteria and were included in the review. 
Figure 6  Flow diagram of literature search 
 
 
Qualitative and quantitative research has been conducted across multiple healthcare settings 
exploring the barriers to using evidence from economic evaluation and the strategies to overcome 
them. The studies were conducted using surveys,15, 75, 80, 81, 85, 87-91, 93, 95, 98, 101-103, 106, 115, 117, 118, 121, 123, 208, 
209 interviews,16, 17, 19, 73, 76, 82-84, 86, 87, 97, 99, 100, 108, 109, 114, 120, 210-214 focus groups,14, 18, 87, 107, 214 and decision-
making observations14, 17, 19, 82-84, 86, 88, 92, 99, 110, 210, 213-215 of physicians, pharmacists, hospital 
administrators, HTA groups, and politicians. The studies were conducted in multiple settings, 
including Australia,73, 89, 90 Sweden,80, 115, 121 Thailand,81, 100 USA,16, 75, 98, 102, 121, 209 Canada,76, 83-85, 88 97, 99, 
114, 211, 213 Italy,117 UK,14, 17-19, 82, 86, 93, 95, 103, 106, 107, 109, 110, 121, 210, 215 France,91, 95, 121 Germany,95 
Netherlands,95, 108, 120, 212 South Korea,208 and Saudi Arabia.101 There were also surveys conducted 
Europe-wide.15, 87, 123 
Records identified through 
database searching 
(N = 4023) 
Additional records identified 
through other sources 
(N = 84)





(N = 3981) 
Records excluded 
(N = 3370) 
 
Duplicate (N = 3) 
Not in English (N = 3) 
Not full article (N = 118) 
Not an original article 
reporting barriers and 
facilitators (N = 3246) 






(N = 49) 
Records excluded 
(N = 112) 
 
Not in English (N = 2) 
Not full article (N = 10) 
Not an original article 
reporting barriers and 
facilitators (N = 100) 
   
Chapter 3: Adaptation of CFIR 30 
3.3.2 Domain 1: Innovation characteristics 
Within CFIR, innovation characteristics refer to the characteristics of the “innovation” that is to 
be implemented, in this case an economic evaluation (Table 4).140  
Table 4 Results from mapping the innovation characteristics domain to the barriers and 
facilitators of using evidence from economic evaluation  
Construct Barriers Facilitators 
Intervention source Conflicts of interest14, 16, 82, 91, 100, 110 Reporting conflicts of interest 
Economic evaluations commissioned by the 
policymakers themselves122-124 
Increased collaboration between researchers and 
policymakers14, 110 
 
Evidence strength and 
quality 
Poor quality of research informing 
economic evaluations16, 18, 19, 87, 89, 93, 
99 
Poor quality methods used to 
estimate indirect and overhead 
costs87, 109 
Guidelines for conducting economic evaluations216, 
217 
Relative advantage Absence of relevant available 
economic evaluations14, 15, 73, 75, 80-87 
Conflict between the individual ethic 
of the doctor-patient relationship and 
the population ethic of cost-
effectiveness14, 109 
Difficulties translating economic 
evaluations into different contexts18, 
82, 87, 92 
Quality of data89 
Economic evaluations rarely analyse 
the impact that an intervention has 
on equity14, 16, 19, 20, 89, 115, 125  
Equity analysis113 
 
Adaptability Difficulties translating economic 
evaluations into different contexts18, 
82, 87, 92 
Narrow scope of research questions 
typically addressed in economic 
evaluations17, 18 
Making economic evaluations more sensitive to 
questions that healthcare decision-makers need 
answers to14, 73 
Involving all stakeholders in the economic 
evaluation process73 
Trialability None identified None identified 
Complexity Complexity of economic evaluation 
design 16, 19, 82, 87 
Training8, 14-16, 82 
Design quality Poor communication from health 
economists (including overuse of 
jargon)15, 16, 90 
Insufficient description of modelling 
assumptions15, 16, 19, 87 
Complex economic evaluation 
design16, 19, 82, 87 and excessive 
variation14, 16, 80 
Excessive variation in economic 
evaluation methodologies and 
presentation,14, 16, 80 
Simplify language and analysis methods16, 82, 90, 101, 
102 
Appropriately designed summary formats18, 103, 104, 
106 
Guidelines for presenting economic evaluations216, 
217 
Cost Time and cost required to conduct 
economic evaluations14, 87-90 
None identified 
 Decision-makers’ lack of time to 
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The CFIR proposes that there are eight constructs of the innovation characteristics domain that are 
relevant for implementation:  
1. Intervention source refers to whether an innovation is externally or internally developed 
and whether the developers of the innovation have legitimacy. Barriers relating to the 
intervention source for economic evaluations include conflicts of interest14, 16, 82, 110 and lack 
of collaboration between health economists and healthcare decision-makers.14, 110 Whether 
the evaluation is commissioned by the policymakers is an important factor in determining 
if the results change policy.122-124  
2. Evidence strength and quality refers to the evidence supporting the healthcare decision-
makers’ beliefs that the use of the economic evaluation will have the desired outcomes. 
Importantly for economic evaluation, the construct represents the strength of evidence and 
quality of evidence supporting the use of economic evaluation to improve decision-making 
rather than the quality of the economic evaluation itself. Although it is a reasonable 
assumption, it is difficult to assess empirically whether knowing which interventions are 
more cost-effective would improve the efficiency of decision-making.12, 218 It is also a 
reasonable assumption that an economic evaluation that uses better quality clinical 
evidence and follows high methodological standards will be more likely to achieve the 
desired outcome of accurately determining the most cost-effective alternative. 
3. Relative advantage is the perceived advantage of using the economic evaluation for 
decision-making versus the alternative solution—whether following clinical norms or using 
effectiveness analysis alone. Barriers relating to relative advantage include absence of 
relevant available economic evaluations14, 15, 73, 75, 80-87, conflict between the individual ethic 
of the doctor-patient relationship and the population ethic of cost-effectiveness,13, 117, 
Difficulties translating economic evaluations into different contexts,18, 82, 87, 92 quality of the 
clinical data,89 and economic evaluations failing to incorporate decision-relevant factors 
other than cost-effectiveness14, 16, 19, 20, 89, 115, 125 are also elements that fit within the 
construct of relative advantage. 
4. Adaptability is the degree to which an economic evaluation can be tailored to meet local 
needs. The adaptability of an innovation can be assessed by outlining what are the elements 
of the innovation that can and cannot be adapted or altered.140, 219 A decision analytic 
model can be adapted by changing parameters; which can be used to adapt models to 
specific healthcare contexts. Once an economic evaluation is published, that publication 
itself is not highly adaptable—apart from corrections—but the underlying decision analytic 
model can be adapted to specific healthcare contexts. The presentation of the results can 
also be adapted into various summary formats.106 
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5. The trialability of an innovation is the ability to test the innovation on a small scale within 
the organisation. Evidence from an economic evaluation is not highly trialable because 
information is difficult to contain in a controlled way.220  
6. Complexity refers to the perceived difficulty of an economic evaluation and depends on a 
number of factors, including the scope of the changes involved, the centrality of the 
decision-making, and the disruptiveness of those changes.140, 205, 221 Difficulty increases with 
the number of individuals and organisations involved,140, 222 and the extent to which the 
innovation changes standard practice.140 Using evidence from economic evaluation is 
particularly difficult to implement if the evidence needs to be generated, for example in the 
case where an economic evaluation needs to be commissioned or developed internally. The 
difficultly of implementation will also depend significantly on the nature of the intervention 
that the economic evaluation is assessing and the scope of the research question.  
7. Design quality is the perception of the quality of how the intervention is bundled, 
presented, and assembled.140, 223 An economic evaluation can use appropriate methods, but 
would have poor design quality if it is poorly communicated with insufficient descriptions 
of assumptions and data sources. The design qualify of a published economic evaluation 
could be improved by presenting it in a shortened summary form or presenting results 
visually. The bundling of the economic evaluation within a set of clinical practice guidelines 
would also be an important aspect of design quality—providing context for how the 
economic evaluation should be interpreted. 
8. The cost of conducting an economic evaluation needs to be offset by the improvement in 
decision-making associated with knowing the cost-effectiveness of the relevant healthcare 
interventions in order for the economic evaluation to be worthwhile. A further barrier is 
the cost for health professionals to spend the time to access and read the economic 
evaluation. 
Domain 1 is highly represented in the literature of the barriers and facilitators to using evidence 
from economic evaluation. However, some of the terminology requires adaptation because several 
constructs within the domain are non-intuitive when applied to economic evaluation. Specifically, 
the construct of evidence strength refers to the evidence that using economic evaluation improves 
healthcare decision-making, while evidence strength is used in reviews of economic evaluation to 
refer to the quality of methods used in economic evaluation. Similarly, the CFIR construct of 
design quality has a different interpretation to the usual use of how economic evaluations are 
defined by quality. It is valid to talk about evidence strength for the use of economic evaluation—
although the construct of evidence strength can easily be confused with the evidence strength of 
the economic evaluation itself. Moreover, the design quality used within CFIR has a different 
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meaning to how design quality is typically used for defining an economic evaluation. When an 
economic evaluation is described as good quality it means that the economic evaluation meets 
certain standards of rigour.  
A simplified version of the constructs specific for economic evaluation is presented in Table 5. For 
parsimony and clarity the eight constructs of the CFIR were simplified to three: relevance, 
accessibility, and credibility. The three constructs were adapted from the Accessibility-Acceptability 
Framework, providing a link between the generalised CFIR framework and the economic 
evaluation specific Accessibility-Acceptability framework. 
Table 5 Mapping relevance, accessibility, and credibility to the innovation characteristics 
domain 
Adapted construct CFIR construct 
Accessibility Complexity 
 Design quality 
 Cost 
Relevance Relative advantage 
 Adaptability 
Credibility Evidence strength and quality 
 Intervention source 
 Trialability 
CFIR, Consolidated Framework for Implementation Research 
 
Accessibility has the same definition as in the Accessibility-Acceptability Framework (and includes 
complexity, design quality and costs). By contrast, acceptability had to be defined differently 
because as originally defined it overlaps with the innovation domain, the characteristics of 
individuals, and the setting—particularly the inner setting domain. Therefore, the construct of 
accessibility was separated into the two components of an economic evaluation that determine 
accessibility: relevance and credibility.  
Relevance refers to whether an economic evaluation is applicable to the specific decision-making 
context. Factors that determine relevance include the research question addressed by the evaluation, 
the outcomes assessed, the adaptability of the evaluation, the timeframe of the evaluation, and the 
notion of value (adaptability and relative advantage from CFIR). 
Credibility refers to the trustworthiness of the economic evaluation. The credibility depends on the 
quality of the modelling methods and clinical data, and the intervention source—the expertise of 
the health economist and any conflicts of interest.  
Herein, the first domain is represented only by the three constructs of accessibility, relevance, and 
credibility. 
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3.3.3 Domain 2: Outer setting 
The outer setting (Table 6) is the economic, political, and social context in which the healthcare 
decision-maker’s organisation operates.140  
Table 6 Mapping the outer setting domain to the barriers and facilitators of using evidence 
from economic evaluation 
Construct Barriers Facilitators 
Patient needs and resources None identified None identified 
Organisational networks None identified None identified 
Peer pressure None identified None identified 
External policies and 
incentives 
Incentives for short-run decision-
making117, 118 
None identified 
Factors without defined constructs 
Public attitudes and values Attitudes to rationing by cost-
effectiveness14, 73, 86 
 
 
The CFIR defines the outer setting by four constructs:  
1. Patient needs and resources. An important determinant for whether an innovation is 
implemented in the healthcare system is the patients’ needs for the innovation. Patient 
needs and resources were not, however, identified as relevant for the use of evidence from 
economic evaluation in the literature. Economic evaluations are predominantly used to 
measure patient needs and resources rather than garner inputs from patients, which can 
explain why patient needs and resources was not identified as a factor relevant for the use 
of evidence from economic evaluation.  
2. Organisational networks refers to the networks between the organisation and external 
organisations. For instance, increased networks between hospitals could facilitate the 
diffusion of evidence from an economic evaluation. 
3. Peer pressure has an impact on the implementation of innovations as people change their 
behaviour in response to their peers changing attitudes and behaviour. Healthcare 
professionals will be more likely to use evidence from economic evaluations in decision-
making if other health professionals are using evidence from economic evaluations. 
4. External policies and incentives were seen to have a substantial impact on whether 
evidence from economic evaluation translated into healthcare policy or practice. Decision-
makers found that policies and incentives encourage them to focus on short run decision-
making—limiting the value of long-term insights from economic evaluations.117, 118 
Financial incentives and policies play an important role in the uptake of research.224, 225 
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There are few financial incentives for scientists and policy-makers to take the initiative to 
build a dialogue with their counterparts.226 
The attitudes and values of the public were identified as a factor that might influence the translation 
of evidence from economic evaluation.14, 73, 86 However, public attitudes and values do not fit within 
the constructs of the Outer Setting domain as defined. Hostile public opinion particularly about 
rationing by cost-effectiveness can be a determinant of implementation that has a greater impact on 
evidence from economic evaluation compared with the innovations typically characterised using the 
CFIR. Public values for health states and the ability to measure these values also impact 
implementation, particularly when economic evaluations fail to consider all of society’s health 
objectives.25 
3.3.4 Domain 3: Inner Setting 
The inner setting is the structural and cultural context of the organisation in which the innovation is 
to be implemented (Table 7)140, 227. In the case of economic evaluations the inner setting might be 
national advisory committees, such as the PBAC, MSAC, state health departments, hospitals or any 
organisation that individual healthcare decision-makers are working within.  
Table 7 Mapping the inner setting domain to the barriers and facilitators of using evidence 
from economic evaluation 
Construct Barriers Facilitators 
Structural characteristics Difficulties in transferring resources 
between sectors and adjusting 
budgets for new therapies14, 15, 76, 82, 87, 
114 
Lack of relevance to local context91, 
100 
Difficulty with disinvestment8, 14, 40, 
115, 116 
Potential economic benefits of 
interventions highlighted in 
economic evaluations are not being 
realised in practice14, 15, 82 
Making economic evaluations more relevant to the 
decision-making context14, 73 
Allowing flexibility in decision-making budgets to 
adopt recommended changes 
Incorporating budget and resource reallocation 
constraints in economic models119, 120 




None identified Set routines, established practices, and rules 
coordinating their relations to stakeholder 
institutions114 
Culture Organisational willingness to trade 
between health gains and cost 
214, 215 
Professional power imbalance215 
None identified 
Implementation climate None identified Reacting to perceived problems215 
 
The inner setting domain is characterised by four constructs: 
1. Structural characteristics is the construct that defines the inner setting in terms of the 
level of the capacities, knowledge, and resources available to the organisation and how the 
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labour, knowledge and resources are coordinated. The structure of an organisation includes 
the official roles and responsibilities, hierarchy, and procedures. Questions relevant to this 
construct include: How many individuals in the organisation have training in economic 
evaluation? How diverse is the organisation? What are the groups of people who make up 
the organisation? How are the different groups coordinated?  
2. Networks and communications refer to the nature and quality of formal and informal 
communications within an organisation. This construct characterises the internal setting of 
an organisation by the extent to which individuals in the organisation are able to 
communicate with each other, and the level of cohesiveness within organisations. 
3. Culture refers to the norms, values, and assumptions of an organisation.228 One 
explanation of failure of implementation is that the initiatives failed to understand the 
culture and the cultural changes required for the implementation to be successful.140, 229 
Andrew Pettigrew defines culture as the system of “publicly and collectively accepted 
meanings operating for a given group at a given time”.230 Pettigrew emphasised the central 
role of symbols to understanding organisational culture through the processes of character 
formation and organisational sagas; how narratives define the organisations’ culture.  
4. Implementation climate refers to how the receptivity of a culture to change can be in 
flux. Characteristics of an organisation receptive to change include140 the perception that 
current situation is seen as intolerable;205, 231 compatibility with organisational values, 
workflows and systems;197, 205 relative priority of the innovation within the organization;197, 
223, 232 and organisational incentives for change.223, 233 
The current literature on the barriers and facilitators to using evidence from economic evaluation in 
healthcare decision-making neglects the inner context relative to the Innovation Characteristics 
domain. This relative neglect of the inner context might be because of the nature of the research 
studies where decision-makers were asked to consider their use of economic evaluations. Under the 
circumstances, the salient factors might be the characteristics of the evaluation rather than the 
structure and culture of the organisation they work for.  
3.3.5 Domain 4: Characteristics of individuals 
One way of thinking about the process of evidence from economic evaluation changing healthcare 
practice can be as a series of individuals deciding whether to use the evidence to change their own 
behaviour (Table 8).  
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Table 8 Mapping the characteristics of individuals domain to the barriers and facilitators of 
using evidence from economic evaluation 
Construct Barriers Facilitators 
Knowledge and beliefs about 
the intervention 
Poor awareness of current 
evaluations13, 14, 16, 17, 86, 100214  
Lack of economic evaluation expertise 
amongst decision-makers8, 14-17, 19, 80, 90, 
91, 93, 95-102, 214 
Negative opinion about economic 
evaluation, including use of QALYs,14, 
16, 108 methods used to estimate indirect 
and overhead costs87, 109, cost-
effectiveness threshold,14, 19, 81, 82, 87 or 
explicit rationing126 14, 73, 86 
Conflict between the individual ethic of 
the doctor-patient relationship and the 
population ethic of cost-effectiveness14, 
109 
Training decision-makers in how to use 
economic evaluations8, 14-16, 82 
 
Self-efficacy Decision-makers’ lack of time to 
evaluate research8, 17, 90 
None identified 
Individual stage of change None identified None identified 
Individual identification with 
organisation 
None identified None identified 
QALYs, quality-adjusted life-years 
The four constructs in the CFIR that constitute the characteristics of individuals domain are: 
1. Knowledge and beliefs about the intervention. An individual making the decision to 
use evidence from an economic evaluation will do so based on their knowledge of 
economic evaluation and their beliefs about using economic evaluation in healthcare 
decision-making. A lack of understanding of economic evaluation is a barrier to use. 
Positive attitudes about an innovation, for instance economic evaluation or the 
interventions assessed in an economic evaluation, promotes use of that innovation. 
Positive attitudes help shape the intention to change behaviour. The converse is also true, 
negative attitudes about economic evaluation or rationing by cost-effectiveness is a barrier 
to the use of evidence from economic evaluations, resulting in negative attitudes, resulting 
in little or no behaviour change from the status quo. 
2. Self-efficacy. The individual’s beliefs in their own capacity to execute a course of action is 
an important determinant of implementation.140, 234 With regards to using economic 
evaluation for healthcare decision-making, self-efficacy means more than being able to 
understand the economic evaluation, the individuals need to have the belief that they can 
enact the changes required to make the decision that is guided by the economic evaluation. 
Individuals with high self-efficacy are more likely to make changes in behaviour, such as 
responding to evidence from economic evaluations, and more likely to sustain changes in 
behaviour.140 
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3. Individual stage of change. The stage of change of individuals trying to implement an 
intervention impacts on the success of the implementation. The individual stage refers to 
the point they are at in their readiness for change. There are a number of theoretical 
models for an individual’s stage of change.174, 221, 223, 235 The more individuals at later stages 
of change the greater the likelihood of successful implementation. The individual’s stage of 
change is linked to the organisations readiness to change (CFIR inner setting domain). 
Even when evidence from economic evaluations does not change policy decisions, notions 
of costs and benefits have become pervasive.17 Decision-makers might not be using formal 
economic evaluations to inform decision-making, but they still use notions of efficiency 
and opportunity costs in decision-making. 
4. Individual identification with an organisation defines the individual in terms of how 
they perceive the organisation and their role within the organisation.  
Both of the constructs of individual stage of change and individual identification with organisation 
were not identified in the literature review of the barriers and facilitators to using evidence from 
economic evaluation. There is scope for greater attention to the impact of individual stage of 
change and identification with organisation in the translation of evidence from economic 
evaluations.  
3.3.6 Domain 5: Process 
The process domain encompasses the stages involved in the development, implementation and 
evaluation of an innovation (Table 9).  
Table 9 Mapping the process Domain to the barriers and facilitators of using evidence from 
economic evaluation 
Construct Barriers Facilitators 
Scoping Training decision-makers in how to use 
economic evaluations8, 14-16, 82 
Involving all stakeholders in the 
economic evaluation process73 
 
Narrow scope of research questions 




Absence of relevant available economic 
evaluations for decision-makers14, 15, 73, 75, 80-
87 
None identified 
Diffusion and dissemination None identified None identified 
Deliberation None identified None identified 
Monitoring and reflection None identified None identified 
Stages adapted from other implementation frameworks145, 236, 237 
 
Here the stages within CFIR have been augmented to include the stage of pre-implementation 
(development) as included in other frameworks132, 145, 205—which is a stage particularly relevant to 
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the implementation of evidence from economic evaluation because considerations about 
implementation should influence development. Altogether there are five stages in the process: 
1. Scoping involves determining the research question and the scope of the research to be 
addressed in the economic evaluation. 
2. Development involves doing the economic evaluation and includes any supporting 
materials, refining and creating different versions of the economic evaluation to be 
appropriate for various audiences, and determining the likely impact that the results of the 
evaluation could have on healthcare practice.132, 145 
3. Diffusion and dissemination are the ways the evidence from the economic evaluation 
are communicated. Diffusion and dissemination does not include the active process of 
addressing the barriers to using evidence from economic evaluations.  
4. Deliberation is the point where the decision that is to be informed by the economic 
evaluation is made.  
5. Monitoring and reflection is the final stage in the implementation process. Monitoring 
and reflection can take the form of feedback through standardised surveys, telephone 
interviews, and focus groups. Standardised surveys are the most common method of 
evaluation for HTA agencies.8 The objectives to be evaluated should be specific, 
measurable, attainable, relevant and timely (SMART).140, 238 Key outcomes for evaluations 
include level of awareness and knowledge of target groups, changes in clinical health 
practices, changes in institutional policies, and changes in government policies.144 
Several of the stages in the process domain did not have barriers or facilitators identified with them. 
It is unknown whether the absence of barriers and facilitators relating to the stages is due to the 
limitations of the qualitative literature investigating the determinants of translation of evidence 
from economic evaluation. 
3.3.7 CFIR adapted for Economic Evidence (CFIR-EE) 
Each of the CFIR domains is represented by barriers and facilitators identified in the literature 
review, although not all of the constructs are represented because there is a paucity of research in 
certain areas. In some cases the constructs might not be represented because of the nature of the 
qualitative research that identified the barriers, where healthcare decision-makers were asked about 
their attitudes to using evidence from economic evaluation. The nature of the research question 
makes the characteristics of the economic evaluation more salient than other domains; the domains 
of inner setting, outer setting, individual decision-maker, and process all had fewer identified 
barriers and facilitators than the characteristics of the innovation domain. Only one of the barriers 
   
Chapter 3: Adaptation of CFIR 40 
or facilitators identified—public attitudes to rationing by cost-effectiveness—did not fit within any 
of the CFIR constructs. Public attitudes did, however, fit within the outer setting domain, so public 
attitudes represents a unique construct relevant to using evidence from economic evaluation.  
The CFIR-EE differs from the original CFIR in four ways (Figure 7). 




CFIR, Consolidated Framework for Implementation Research adapted for Economic Evidence 
 
The first difference is that the innovation domain now consists of only three constructs (Section 
3.3.2)—accessibility, credibility, and relevance. The three constructs represent the overarching 
factors that must be balanced in the development of the economic evaluation at each stage of the 
process in consideration of the characteristics of the individuals involved and the context in terms 
of the inner and outer setting.  
The second difference is the inclusion of public attitudes as a construct within the outer setting 
domain. The public attitudes construct characterises the outer setting in terms of the perceptions in 
the community about rationing by cost-effectiveness. 
The third difference is that the characteristics of the economic evaluation interact with the inner 
setting domain, the characteristics of individual decision-makers domain, and the outer setting 
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impact on the attitudes and knowledge of the decision-makers and lead to changes in the inner and 
outer setting domains. The interactions between the domains are represented in a graphical change 
from the original framework. The process as a domain links (with arrows) the characteristics of the 
economic evaluation domain with the individual decision-makers and the inner and outer settings. 
The individual decision-maker domain is graphically represented within the inner setting domain. 
The final difference is that the stages in the process domain have been redefined to be more 
relevant for economic evaluations (Section 3.3.6). Stages of scoping and development were 
included in the CFIR-EE because the production of the economic evaluation itself is a crucial stage 
in translating evidence from economic evaluations into healthcare policy and practice.   
The adaptations were predominantly driven by the mapping of the evidence of the barriers and 
facilitators review but where supplemented by expert knowledge and the nature of the innovation. 
It should be noted here that the mapping represents the first stage of the adaptation of the 
framework for economic evidence and it is likely that future research and development will result in 
later changes to the framework. 
3.4 DISCUSSION 
The CFIR-EE provides a theoretical framework to understand the translation of evidence from 
economic evaluations into healthcare policy and practice. The CFIR-EE represents the translation 
of evidence from economic evaluation within a broader implementation context. The adaptation of 
the CFIR was informed by the Accessibility-Acceptability framework; specifically, in the definition 
of the constructs within the characteristics of the economic evaluation domain. 
The CFIR-EE highlights the multilayered interactions between the economic evaluation, individual 
decision-makers and the context that the decision-makers work in. The CFIR-EE has a number of 
strengths as a framework for understanding the factors that determine the translation of evidence 
from economic evaluation into healthcare policy and practice. The CFIR-EE makes explicit that the 
implementation process begins with the conception and development of the economic evaluation, 
includes multiples stages of diffusion, dissemination and active implementation strategies, and 
finally an evaluation of the success of the implementation strategy. 
The eight constructs within the characteristics of the economic evaluation domain were simplified 
into three constructs. The terminology of some of the constructs in the CFIR is misleading when 
the innovation under scrutiny is a type of evidence. The evidence strength and quality of the 
medical device refers to the strength of the evidence that supports the use of the medical device, 
the equivalent for an economic evaluation is not the quality of the evaluation but the strength of 
evidence that supports the use of economic evaluations generally. Similarly, design quality has a 
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different meaning when applied to evidence from economic evaluation to when applied to another 
innovation, such as a medical device. 
Some of the terminology and concepts within the CIFR constructs and domains needed to be 
adapted when relating to the implementation of a type of evidence and a method of evidence 
synthesis such as economic evaluation. CFIR characterises innovations by their evidence base. 
However, evidence itself, such as evidence from economic evaluations, can also be an innovation. 
CFIR remains valid when the innovation is evidence, but some of the terminology within the 
framework requires clarification. Furthermore, evidence from economic evaluation, as an 
innovation, affects the relationship between the domains 
The nature of the qualitative studies from the literature review might have had an impact on which 
domains were well represented in the identified barriers and facilitators to using evidence from 
economic evaluations in healthcare decision-making. The most well represented CFIR-EE domain 
was the characteristics of the evaluation—which is likely to include the most salient factors for 
healthcare decision-makers asked specifically about why they do or do not use evidence from 
economic evaluations. However, and importantly, it should not be concluded that the greater 
representation implies that the characteristics of the evaluation have a greater impact on the success 
of the translation process than the other determinants. The relative influence on successful 
implementation of each domain is a question for future research. 
The mapping process conducted to develop the CFIR-EE only incorporated the barriers and 
facilitators for getting evidence specific to economic evaluations into practice, rather than other 
types of evidence. However, the original CFIR was based on findings from a wide range of 
implementation settings within health and healthcare. How the CFIR should be applied or adapted 
to other types of evidence remains a topic for further research.   
The CFIR-EE represents a comprehensive and relevant framework in which to better understand, 
structure and implement the translation of economic evidence.  
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4 MEASURING DECSISION MAKER’S 
PREFERENCES FOR THE ATTRIBUTES OF 
ECONOMIC EVALAUTIONS 
4.1 INTRODUCTION 
Preferences for a good can be revealed through behaviour. Consumer preferences can often be 
understood through a close analysis of purchasing behaviour and how the behaviour responds to 
factors such as price, or distance, or other attributes that define the good. Revealed preference 
methods, however, require an existing market for the good under investigation.  
An alternative approach in the absence of a market is stated preference analysis. Stated preference 
analysis is a family of survey techniques designed to elicit people’s preferences for goods. 
Contingent valuation and choice analysis are two common types of stated preference techniques.  
In contingent valuation, people are told to consider a hypothetical opportunity and directly asked 
how much they would be willing to pay.31, 239 Often the outcome of a contingent valuation is the 
respondents’ willingness to pay measured in monetary terms. Contingent valuation can also be used 
to elicit other valuation preferences such as willingness to wait or willingness to travel. 
Choice analysis also provides a method of eliciting willingness to pay, wait or travel.240, 241 However, 
in choice analysis respondents are not asked to directly value a good. Rather they are provided with 
alternative options. The choices between the options provide information about preferences and 
how much the people value the goods.  
Discrete choice experiments are a common and well studies choice analytic technique. Discrete 
choice experiments allow for the measurement of preferences for individual attributes of a good or 
service (such as an economic evaluation).215, 242, 243 It is a method that has been used to value 
preferences for healthcare services and the healthcare system more widely.244, 245 A discrete choice 
experiment is more realistic than simply asking respondents what they prefer as it forces the 
respondents to make a choice.131 As a method it is consistent with economic demand theory, 
specifically Lancaster’s theory of value246—that it is the characteristics or attributes of a good that 
determines the good’s value. Unlike other stated preference techniques, discrete choice experiments 
allow for scale comparisons.247 There is growing evidence that the nature of the decisions made in 
discrete choice experiments can be more intuitive compared with other stated choice methods.248 
Studies have found that respondents answer discrete choice experiments in a way that is internally 
valid and consistent.249-251 
Previous work using discrete choice experiments include measuring patient preferences for health 
services and health outcomes, professional preferences for occupation factors and nature of 
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treatments, preferences for which patients should receive priority, and what factors should be 
considered in healthcare decision-making.244, 252, 253 Discrete choice experiments have also measured 
preferences for decision-making criteria for use in HTA.20, 49, 125, 254-258 Decision-making criteria 
assessed in these studies included incremental cost-effectiveness,49, 125, 254-258 uncertainty of the cost-
effectiveness,49, 125, 258 distributional or equity impact,20, 125, 259 absolute health benefit of treatment,20, 
49, 256-258 number of potential beneficiaries and their characteristics,49, 256-258 severity of the disease 
before treatment,256, 257 budget impact and affordability,49 and accessibility in terms of waiting times 
and travel distance.20 Although discrete choice experiments have measured preferences for cost-
effectiveness as a decision criterion and have been used to estimate parameters for economic 
evaluations, none to date have assessed the factors that make economic evaluation valuable for 
decision-making. 
This is the first study to apply quantitative discrete choice experiment methods to value preferences 
for the design and conduct of an economic evaluation. The results demonstrate the trade-offs that 
healthcare decision-makers are prepared to make when choosing an economic evaluation. By 
understanding the preferences of healthcare decision-makers for the design and conduct of an 
economic evaluation, health economists can better meet healthcare decision-makers’ needs and 
facilitate the translation of their research into healthcare policy and practice.  
4.2 METHODS 
4.2.1 Participants 
The eligible population included healthcare professionals, health administrators, health managers, 
and health researchers. Multiple methods were used to recruit participants during a five month time 
period from February to June 2015. Emails were sent through professional mailing lists including 
those of the Australian Centre of Health Services Innovation (AusHSI) and Health Services 
Research Association of Australia and New Zealand (HSRAANZ). Nationality was not an eligibility 
criterion, although the recipients of these mailing lists are predominantly from Australia and New 
Zealand. Participants attending AusHSI economic evaluation workshops were informed of the 
survey. Flyers for the survey were posted at International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and HSRAANZ conference. The recruitment involved snowballing; 
where respondents were asked to forward the link of the survey to people they thought would be 
interested.  
4.2.2 Design of the discrete choice experiment 
A discrete choice experiment was designed, following best practice guidelines,227, 230, 241 to elicit 
preferences for the design and conduct of an economic evaluation. Attributes were identified 
through a literature review of barriers to using evidence from economic evaluation in healthcare 
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decision-making13 and the framework developed by Williams et al.,210 and represent features of an 
economic evaluation that effect the relevance, accessibility, and credibility of an economic 
evaluation. A convenience sample of healthcare professionals were surveyed to confirm the 
attributes and was used to select the subset used in the final discrete choice experiment (see 
Appendix B). The survey assessed importance of the attributes using five-point Likert scales, and 
asking respondents to rank their two most and least important attributes. The responses to the 
questions were used to select the seven attributes, with each attribute having three levels.  
The discrete choice experiment design software package NGENE was used to develop the 
orthogonal fractional factorial design.246 There were no combinations of levels for the attributes 
that were considered implausible. The experimental design resulted in 18 binary choice sets for 
presentation. Respondents were randomised to receive one of two blocks each consisting of nine 
choice sets to reduce the cognitive burden of answering the questionnaire. There was also a repeat 
choice set that was not included in the statistical analysis but was used as a consistency check—
respondents who were not consistent between the duplicate choice sets were excluded from the 
analysis.248, 260  
Respondents were asked to consider a hypothetical scenario where two health economists are 
available to provide supporting evidence to make a decision on whether a hospital should fund a 
new piece of equipment. The scenario was chosen to be a situation where it would be feasible that 
an economic evaluation would be used for a concrete, easy to understand decision. The equipment 
was not defined, because it would need to be relevant across specialties. Respondents were asked 
which health economist they would choose. The attributes of the discrete choice experiment were 
the distinguishing features of the economic evaluations. A forced choice design was used248, 261—in 
each choice the respondent had to select one of the health economists, without the choice of 
picking neither. The health economists were labelled “Economist A” and “Economist B”, giving no 
additional information beyond the attributes and levels. All other factors were assumed to be 
constant.  
4.2.3 Administering the questionnaire 
The questionnaire was conducted online (see Appendix C). The front section of the questionnaire 
provided participant information and confirmed consent to participate. The questionnaire was 
piloted with 15 respondents. Findings from the pilot questionnaire were used to clarify the scenario 
and definitions of attribute levels. Some minor changes to the questionnaire layout and phraseology 
relating to one of the attribute levels were made as a result of the pilot survey to facilitate 
respondent understanding and completion. The descriptions of the final attributes and levels 
included in the discrete choice experiment are presented in Table 10. 
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In addition to the discrete choice experiment, the questionnaire included a series of demographic 
and attitudinal questions. Demographic questions included profession, gender, and previous 
experience with economic evaluation. The respondents were asked to rank on five-point Likert 
scales how useful they thought cost-effectiveness information is to decision-making, and how 
difficult they found the questionnaire to complete. An example choice set was provided at the 
beginning of the survey along with pre-test questions so that respondents could habituate to the 
nature of the task and confirm their understanding. 
4.2.4 Data analysis 
Preferences were analysed using conditional (fixed-effects) logistic regression in STATA.242 Time 
was continuously coded (in months) after it was confirmed that the level effects were linear. Other 
attributes were effects coded.262 The coefficients in the model indicate the relevance of those 
attributes to the choice of economist. A positive coefficient indicates that the attribute makes the 
economic evaluation more valuable while a negative coefficient indicates that the attribute detracts 
from the value of the economic evaluation. Willingness to wait was calculated by dividing the 
regression coefficient attached to the respective attribute level by the coefficient attached to time 
(treated as a continuous variable).  
4.3 RESULTS 
4.3.1 Preliminary survey 
A convenience sample of 35 health professionals completed the preliminary survey. The difference 
in the mean rankings was similar between the attributes, indicated that all the attributes were 
considered important. The attributes from most to least important were quality of clinical evidence 
(m = 4.49; SD = 0.65), clearly stating assumptions (m = 4.30; SD = 0.62), making cost-
effectiveness studies easier to understand (m = 4.30; SD = 0.85), using the simplest valid approach 
to measuring cost-effectiveness (m = 4.22; SD = 0.89), rigour of methods used to estimate cost-
effectiveness (m = 4.14; SD = 0.72), avoiding conflicts of interest (m = 4.08; SD = 0.89), budget 
impact analysis (m = 4.00; SD = 0.68), professional training in interpreting and evaluating cost-
effectiveness studies (m = 3.97; SD = 0.76), considering equity effects of healthcare intervention in 
cost-effectiveness studies (m = 3.78; SD = 0.85), considering clinical need (m = 3.76; SD = 0.80), 
and length of time required to conduct the cost-effectiveness study (m = 3.69; SD = 1.00). 
When the respondents were asked which two attributes they would rank as most important the 
attributes that were chosen most often were quality of clinical evidence (48.7%), using the simplest, 
valid approach to measuring cost-effectiveness (32.4%), and avoiding conflicts of interest (18.9%). 
When the respondents were asked which two attributes were least important the attributes that 
were chosen most often were “length of time required to conduct the cost-effectiveness study” 
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(62.9%), “considering clinical need of healthcare interventions in cost-effectiveness studies” 
(28.6%), “avoiding conflicts of interest” (25.7%), “considering budget impact of healthcare 
interventions” (22.9%). 
Time was not one of the most preferred attributes, but it was included within the discrete choice 
experiment because it is a factor with established relevance for real-world decision-making. As an 
attribute time is context specific so its value is likely to be greater when a scenario is provided, such 
as with a discrete choice experiment. The other advantage of using time as a variable is that it can 
be used to calculate willingness to wait. Conflict of interest was included because it was “very 
important” to a subset of the respondents. All of the attributes related to communication, training, 
and parsimony were viewed as roughly equal in importance, so the attributes were collapsed into a 
single communication attribute with training and parsimony included in the definition.  
Respondents were asked to describe other characteristics of an economic evaluation that are 
important. The most common response was making sure that the economic evaluation was relevant 
to the specific clinical setting. Therefore the ‘applicability’ attribute was included in the discrete 
choice experiment. 
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Table 10 Attributes and levels 
Attribute Definition Levels 
Quality of 
clinical evidence 
Level of bias in the clinical evidence informing 
the cost-effectiveness study. 
Good quality – Multinational randomised controlled trial with large sample size or systematic review of multiple 
randomised controlled trials. Low risk that bias, confounding or chance may have influenced the results. Conducted 
in relevant population and generalisable. 
Fair quality – A small randomised controlled trial or a good quality observational study. Moderate risk that bias, 
confounding or chance may have influenced the results. 




Level of bias in the economic modelling 
techniques. 
Good quality – Most accurate measure of cost-effectiveness given quality of clinical evidence; all relevant economic 
consequences identified, measured, and valued accurately. 
Fair quality – Reasonably accurate measure cost-effectiveness given quality of clinical evidence; most relevant 
economic consequences identified, measured, and valued accurately. 
Poor quality – Inaccurate measure of cost-effectiveness given quality of clinical evidence; economic consequences 
not accurately identified, measured, or valued. 
Length of time Time to produce the cost-effectiveness study 
between first contact with the health economist 




Communication How easy is it to understand the cost-
effectiveness study? 
Good – Easy to understand. Avoids unnecessarily complex methods or jargon. 
Fair – Mostly understandable. Some unnecessary complexity of methods and some jargon. 
Poor – Difficult to understand. Unnecessarily complex methods with heavy use of jargon. 
Equity How is the fairness (equity) impact of the piece 
of equipment assessed? 
Thorough analysis – Potential costs and consequences across socioeconomic and cultural groups analysed in detail. 
Mentioned – Discussion of potential costs and consequences across socioeconomic and cultural groups. 
No consideration – No discussion of costs and consequences across socioeconomic and cultural groups. 
Applicability How applicable are the results to the decision-
making context? 
Specifically applied to context– Applied to specific hospital, department, or other healthcare context. Includes 
thorough budget impact analysis. 
Generally applied to context– Applied to general decision-making context (Australian healthcare setting). Budget 
impact estimated. 
Not applied to context– Not specifically applicable to the decision-making context. Conducted in a different context 
(e.g. in another country). No budget impact analysis. 
Conflict of 
interest 
Whether the health economist is employed by 
or receives funding from a company with 
financial interests in the results of the cost-
effectiveness study. 
No conflict – Health economist is not employed by or has received any funding by a company with financial 
interests. 
Independent with industry funding – Health economist works at a university but has received research funding from 
industry. 
Employed by industry – Health economist is an employer of a company with direct financial interests. 
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4.3.2 Characteristics of respondents 
Ninety respondents completed the main survey and answered all ten choice comparisons. Nine 
failed the consistency check and were removed from the analysis, leaving a final sample of eighty-
one. Table 11 presents the demographic details of the respondents. A total of 37 (46%) 
respondents were health professionals, 33 (41%) health researchers, and 18 (22%) were health 
managers and administrators (7 respondents were health professionals who also had either a 
managerial or research role). The majority of the respondents (91%) lived and worked in Australia 
and the majority were female (70%).  
Many of the respondents indicated that they had a pre-existing interest in economic evaluation. 
Thirty-five (43%) respondents had received previous training in cost-effectiveness, mostly in the 
form of workshops or individual lectures. The majority of respondents thought that cost-
effectiveness evidence was “useful” or “very useful” for healthcare decision-making (65%) and had 
at least sometimes used cost-effectiveness evidence for healthcare decision-making (62%). Several 
respondents had been involved in developing (20%) or commissioning (14%) economic evaluations 
or had worked with a health economist (37%). When asked how difficult they found the survey 
31% found it “not difficult”, 53% “slightly difficult”, 13% “difficult”, and 2% “very difficult”. 
Table 11 Characteristics of respondents and their experiences with economic evaluation (N=81) 
Characteristics Categories N (%) 
Gender Female 57 (70.4%) 
Male 21 (25.9%) 
Other/Not answered 2 (2.5%) 
Profession category Health professional 37 (45.7%) 
Health manager/administrator 18 (22.2%) 
Health researcher 33 (40.7%) 
Previous training in economic evaluation Yes 35 (43.2%) 
No 46 (56.8%) 
Previous worked on economic evaluation Yes 16 (19.8%) 
No 65 (80.2%) 
Previous commission of economic evaluation Yes 11 (13.6%) 
No 70 (86.4%) 
Previous worked with health economist Yes 30 (37.0%) 
No 51 (30.0%) 
How often do you use cost-effectiveness information for 
healthcare decisions? 
Never 16 (19.8%) 
Seldom 15 (18.5%) 
Sometimes 35 (43.2%) 
Often 12 (14.8%) 
Almost always 3 (4.3%) 
How often do you think you should use cost-effectiveness 
information for healthcare decision-making? 
Never 3 (3.7%) 
Seldom 4 (4.9%) 
Sometimes 17 (21.0%) 
Often 38 (46.9%) 
Almost always 19 (23.5%) 
How useful do you think cost-effectiveness information is for Slightly useful 5 (6.2%) 
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healthcare decision-making? Fairly useful 13 (16.0%) 
Useful 30 (37.0%) 
Very useful 23 (28.4%) 
 
4.3.3 Analysis of preferences 
The conditional logistic regression model revealed a good model fit (McFadden’s pseudo-
R2=0.267). The β-coefficients of the model, representing the preference weights associated with the 
attributes are presented in Table 12 and Figure 8. Respondents exhibited statistically significant 
(p<0.05) preferences for fair and good quality clinical evidence, good quality economic modelling, 
having a shorter time to wait (in months) for the completion of the economic evaluation, good 
quality communication, thorough analysis of equity impact applicability (general or specific), and 
having no conflicts of interests. The greatest willingness to wait was for good quality economic 
modelling (19.8 months), good communication (14.9 months), avoiding conflicts of interest (12.9 
months), and good quality evidence (11.3 months). Respondents were also willing to wait almost a 
year to make sure that the evidence is generally (8.3 months) or specifically (10.1 months) applicable 
to their clinical context. The respondents were willing to wait almost a third of a year (3.7 months) 
to have at least fair quality clinical evidence. 
Table 12 Results of conditional (fixed-effects) logistic regression of respondent choices 
Attribute 
 








Fair 0.25 [0.05, 0.45]  0.02 4.9 




Fair -0.12 [-0.35, 0.12] 0.33 -2.2 
Good 1.20 [0.91, 1.50] <0.01 23.2 
Length of time Per 1 month* 0.05 [0.02, 0.09] <0.01 1.0 
Communication Fair -0.41 [-0.67, -0.15] <0.01 -7.8 
Good 0.79 [0.44, 1.15] <0.01 15.3 
Equity Mentioned -0.08 [-0.27, 0.10] 0.38 -1.6 
Thorough analysis 0.29 [0.06, 0.52] 0.02 5.6 
Applicability Generally applied to context 0.44 [0.24, 0.65] <0.01 8.5 
Specifically applied to context 0.64 [0.42, 0.85] <0.01 12.2 
Conflict of 
interest 
Independent with industry 
funding -0.01 [-0.24, 0.23] 0.97 -0.1 
No conflict 0.74 [0.49, 1.00] <0.01 14.4 
CI, confidence interval; LL, lower limit; NA, not applicable; UL, upper limit 
* Based on attribute levels 1 month, 6 months, 12 months 
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Figure 8 Pattern of healthcare decision-maker preferences for the design and conduct of an 




Whilst previous discrete choice experiments have included preferences for cost-effectiveness as a 
decision-making criterion, this is the first study to assess the aspects of an economic evaluation that 
make it valuable for decision-making. There is a clear preference for a good quality economic 
evaluation that is specifically applicable and communicated well by an independent researcher. High 
methodological rigour was valued, but did not dominate; methodological rigour alone does not 
determine the value of an economic evaluation. The healthcare decision-makers valued timeliness, 
but were willing to wait for an economic evaluation that was high quality in terms of modelling, 
clinical evidence used, and communication.  
Preferences of the respondents were not sensitive to all changes in attribute levels. There was a 
strong preference for good quality economic modelling but no significant difference in preference 
between fair and poor quality economic modelling. The lack of preference for fair quality economic 
modelling could be because the respondents are less familiar with economic evidence than clinical 
evidence – respondents might believe that they can adapt to clinical evidence with moderate level of 
bias but not to economic modelling with moderate risk of bias. The unintuitive findings for 
communication might have a similar explanation; if the evaluation is not completely understandable 
then there is the risk that a crucial element to interpreting the evaluation will not be understood by 
the decision-makers. There was little difference in preference between having a conflict of interest 
through being employed or through being funded by industry. Similarly, although there was a 
preference for a thorough equity impact analysis, respondents did not prefer mentioning potential 
equity impacts over no consideration of equity. The preference for being generally applicable was 
similar to the preference for being specifically applicable.  
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The complexity of the discrete choice experiment task was mitigated by the high levels of education 
of the study population and the design of the survey instrument. Most of the respondents (84%) 
found the survey “Not difficult” or only “Slightly difficult”. Only 10% of the respondents failed the 
consistency check. The blocked nature of the design might have reduced complexity, as the 
respondents only needed to answer ten choice comparisons. The pre-test example choice 
comparison and self-test questions provided further opportunity to understand the nature of the 
choice task. 
An important question with regard to any discrete choice experiment is whose preference should be 
measured. In the case of this study a broad definition of “healthcare decision-maker” was used to 
include not only health professionals but also health administrators and health researchers. 
Subgroup analysis was consistent over the divergent groups indicating that preferences were not 
highly determined by the population whose preferences are assessed. The sample size was moderate 
but in line with studies using discrete choice methods in a similar context, and the sample size was 
sufficient to support the level of analysis conducted. Moreover, the variety of backgrounds that the 
decision-makers were from, and the consistency of their responses increases the generalisability of 
the results. 
The attributes within the discrete choice experiment were limited to factors associated with the 
design of the economic evaluation as these are the most easily modifiable factors, particularly for 
health economists. Potentially, this may make economic evaluation design factors appear to have 
greater importance than factors associated with context, process, or the individuals involved. 
The respondents had greater experience with economic evaluation than would be expected in a 
random sample of health professionals, administrators, and researchers. The greater experience 
with economic evaluation is likely a result of self-selection, where people with an interest in 
economic evaluation were more likely to respond to a request to complete a survey about the use of 
evidence from economic evaluation in decision-making. However, the respondents’ interest in 
economic evaluation is not a limitation, as the sample represents the people who are more likely to 
be using evidence from economic evaluation for decision-making at the margin—and so most likely 
to respond to efforts to make economic evaluations more useful and better quality. 
This is the first study to quantitatively measure what determines the value of economic evaluation 
as a service. The discrete choice experiment is a useful tool for discerning which attributes matter 
most and what trade-offs are possible. The attributes and levels were designed to reflect the 
constraints of producing an economic evaluation and the factors that need to be balanced to 
translate results into healthcare practice. The willingness to wait for the factors that are important 
to healthcare decision-makers—quality of modelling and clinical evidence, good communication, 
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avoidance of conflicts of interest, applicability—supports a pragmatic approach to the trade-off of 
time and quality.  
The findings provide guidance for producing, explaining, and communicating economic evaluations 
to decision-makers. Health economists should aim for high quality methods whilst also ensuring 
that the findings of an economic evaluation are communicated in a manner that demonstrates 
applicability to the healthcare context. This work also suggests that decision-makers prefer to wait 
for good quality research they can understand and trust. 
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5 EXPERIENCES OF HEALTH ECONOMISTS 
TRANSLATING EVIDENCE FROM ECONOMIC 
EVALUATION INTO HEALTHCARE POLICY AND 
PRACTICE 
5.1 INTRODUCTION 
Several studies have investigated the translation of evidence into healthcare policy and practice 
from the perspective of researchers from a variety of fields including clinical practice guidelines,263-
265 and research on health inequality,266 and the research translation priorities of health research 
funding agencies.267 Determinants of practice have been identified in the studies that were not 
identified when only users of evidence were interviewed. The researchers have more detailed 
understanding and have more experience implementing strategies to facilitate the use of evidence.  
Qualitative studies that have investigated the barriers and facilitators to using evidence from 
economic evaluation in healthcare policy and practice have not gathered the perspectives of health 
economists. The objective of this study was to learn from the experiences of health economists 
translating evidence from economic evaluation into healthcare policy and practice, which was 
achieved through semi-structured interviews with health economists. 
The CFIR-EE provides the theoretical framework used in this study (Figure 9; see Chapter 1). 
The CFIR-EE consists of five domains: (1) the characteristics of the economic evaluation; (2) the 
individual decision-makers who use evidence from economic evaluations in healthcare decision-
making; (3) the inner setting where the healthcare decision-making occurs; (4) the outer setting 
representing the wider political, cultural and economic context; and (5) the process of 
implementation. 
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Figure 9 CFIR-EE 
 
  
CFIR, Consolidated Framework for Implementation Research adapted for Economic Evidence 
 
5.2 METHODS 
5.2.1 Data collection 
In-depth interviews were conducted in person with a purposive sample268 of health economists 
recruited from Australia and the UK—two of the world’s leading countries for economic 
evaluation and HTA.61 The health economists were chosen based on their high level of expertise, 
and experience and to reflect a variety of decision-making settings and a variety of economic 
evaluation types. The variety in backgrounds was chosen to allow for the identification of factors 
relating to the setting or the nature of the economic evaluation that influence translation. All of the 
health economists provided consent for the interviews.  
The interviews were organised around three questions: 
1. I would like you to think of an economic evaluation that you have worked on in the past couple of years. 
Preferably one that is now finished. Can you explain the process from the very beginning to the end? 
2. In what ways can the process of producing economic evaluations be improved? 
3. What do you think are the most important things you as a researcher can do to translate evidence from 
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Further questions pursued and clarified emerging themes. An interview guide was developed 
(Appendix D), and was revised during the study. The most significant change was in the manner 
that the questions were asked—the protocol was revised so that at the beginning of the interview 
the health economist would be informed of all three questions that were to be addressed. 
Informing the health economists of all of the questions upfront allowed the health economists to 
focus on the issues that they thought were most important. The interviews were between half an 
hour to an hour long with most being over 45 minutes long. The interviews were audio recorded 
and transcribed non-verbatim by GM.  
5.2.2 Research ethics 
The study was approved by the Queensland University of Technology Office of Research Ethics 
and Integrity (Ethics Clearance Number: 1500000245). Written informed consent was obtained 
from participants prior to commencing the interview. All data were protected and available only to 
the authors. Every effort has been made to ensure that the participants are not identifiable. In order 
to maintain confidentiality, the health economists were given labels (HE1, HE2 etc.). The academic 
titles were organised as either Lecturer or Professor/Associate Professor.  
5.2.3 Data analysis 
Deductive thematic analysis was conducted269 using the CFIR-EE as a theoretical framework. 
There were two steps in the analysis. In the first step the interview transcripts were read and 
participants’ responses on how to translate evidence from economic evaluation into healthcare 
practice were identified and openly coded—identifying elements relating to the translation of 
evidence from economic evaluation into healthcare policy and practice. In the second stage this 
coded content was compared with the constructs and domains of the CFIR-EE to identify where 
the content fit within the domains and constructs of the CFIR-EE and to identify coded content 
that does not fit. Codes were continuously compared between transcripts to ensure consistency and 
comprehensiveness. Quotes from the participants were used to highlight the themes. 
5.3 RESULTS 
5.3.1 Participants 
Nine health economists participated in the semi-structured interviews (Table 13). Four were from 
Australia and five were from the UK. The economic evaluations discussed as examples were a 
range of types including trial-based economic evaluations, modelled economic evaluation, MCDA, 
and one health economist who focussed on methodological rather than applied economic 
evaluation research. The transcriptions of the interviews can be found in Appendix E. 
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Table 13 Participant characteristics 
ID Country Nature of economic evaluation Position 
HE1 Australia Trial-based Professor/associate professor 
HE2 Australia Modelled Lecturer 
HE3 Australia Modelled Professor/associate professor 
HE4 UK MCDA Professor/associate professor 
HE5 UK MCDA/modelled Lecturer 
HE6 UK Trial-based Lecturer 
HE7 UK Modelled Lecturer 
HE8 UK Methodology Professor/associate professor 
HE9 Australia Modelled Professor/associate professor 
MCDA, multiple-criteria decision analysis 
5.3.2 Domain 1: Characteristics of the economic evaluation 
The characteristics of the economic evaluation are the features in the design, methods, and 
presentation of the economic evaluation that are relevant in terms of translation in healthcare policy 
or practice. The domain can be described using three constructs of relevance, accessibility, and 
credibility (Figure 10). As described in Section 2.3.1, an economic evaluation is relevant if it is 
applicable to the specific decision-making context. Accessibility depends on the economic 
evaluation being obtainable, understandable and timely. An evaluation is credible if it is perceived as 
trustworthy, which depends on several factors including the rigour of the methods, the source of 
the evaluation, and expectations of results.  
Figure 10 Characteristics of the economic evaluation 
 
5.3.2.1 Relevance 
Relevance was an implicit factor discussed in all of the interviews, and was explicitly discussed by 
three of the nine participants. Each of the three participants mentioned relevance on more than 
three separate occasions. 
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You mean like research going into the ether? You just publish and that’s it, and you don’t know if it’s 
going to be used or not? I think that’s the majority.  HE7 
The aspects of an economic evaluation that determine its relevance include the research question 
addressed by the evaluation, the need to consider criteria other than cost-effectiveness, and the 
time dependence of the evaluation.  
HE3 discussed the relevance of the research question.  
Make sure that you’re researching a practice relevant question. You really want your question to be driven 
by people in practice addressing a relevant problem. … You could research lots of things, but it’s the ones 
that address real world problems for people in practice or in clinical areas that are likely to be driven ahead 
and taken up by people in clinical practice and that are likely to make a difference. HE3 
HE5 noted the importance of decision-making criteria other than cost-effectiveness, particularly 
budget impact, which was seen as more important than cost-effectiveness by health policymakers at 
the local government level. As pointed out by several of the health economists, sometimes there are 
things that are valued where we cannot put a monetary value on them.  
…we shouldn’t just have a cost-effectiveness health system because that would be a strange thing. We 
wouldn’t save premature babies; we wouldn’t prolong life for terminal cancer when maybe we should prolong 
their life for a year. HE1 
I would probably be one of the first to say cost-effectiveness is important but it’s not the be all and end all. 
To be honest I’d be concerned if we lived in a world where cost-effectiveness was seen as the be all and end 
all. HE3 
HE2 recommended doing economic evaluation within “a broader evaluation framework, considering the 
value of that service to the community and to society and bringing in other principles that are founded in economics—
like rule of rescue and equity issues—but do not fit nicely into a traditional economic evaluation.” Otherwise, “it 
can be misleading in the same way that just looking at effectiveness without the economic evaluation is misleading.” 
HE3, HE4, and HE5 all discussed the potential use of MCDA to aid decisions in situations where 
decision making criteria other than cost-effectiveness should be considered. HE5 discussed the use 
of MCDA to factor innovation in healthcare decision-making. 
…a lot of people thought about how innovation should be captured within economic evaluation. And 
MCDA was initially one of the methods that captured that... HE5 
HE2 discussed the impact of time dependence on the relevance of economic evaluations: 
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I tend to evaluate things within a very short timeframe, which is also challenging because if your programme 
will probably become more efficient over time as you get slicker at doing things and you create more demand 
for your programme. But quite often they are doing it earlier on in the piece. So you get this massive set up 
costs and only a handful of patients in the first few months. HE2 
An implication of these upfront costs is that it can make programs seem less cost-effective than 
they would be in the long term—but perhaps the long term measure of cost-effectiveness is the 
more relevant measure. 
5.3.2.2 Accessibility 
The construct of accessibility refers to whether the economic evaluation is affordable, 
understandable and available in a timely manner. All of the participants discussed accessibility in 
some form; the most common issue was related to the importance of communication. 
Characteristics of communication discussed included choice of language, clear descriptions of 
assumptions, level of detail, precision, explaining concepts, tailoring to mode of 
communication, evidence summaries, and the presentation of results. Other determinants of 
accessibility include cost, timeliness, and complexity of study design. Five of the participants 
referred to some aspect of accessibility at least five times.  
HE3 discussed the importance of explaining research in a way that people understand. 
 It’s important that the people who are interested in the answer to the question can understand what you’ve 
done; otherwise they are not going to believe what you say. But that’s about having them on board and 
ensuring that it is reported in a way that can be understood. HE3 
The language used must be appropriate for the intended audience.  
You need to use the language that makes sense to people from a health background. HE3 
There’s barriers for the reader—the end user—to say “what does this all mean?” It’s got to be in a format 
and language so that they can understand. HE9  
HE3 and HE6 discussed the importance of providing a clear description of assumptions to 
ensure transparency. 
I think it’s about clarity. You’ve got to report in a clear way so that people should be able to understand 
what you have done and it should be clear what assumptions are based on.  HE3 
One thing we learn is that at every step to make clear what we are doing is consistent with their research 
plan and research question; making the economic evaluation design transparent. HE6 
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Several of the health economists discussed their approaches to deciding the level of detail, how 
much or how little to show. The suggestions include finding a compromise between quality and 
relevance, minimising unnecessary details, and not necessarily presenting every analysis that has 
been conducted.  
It was actually a bit of a compromise in a way between what we actually had good data to show and what 
was meaningful in terms of their decision. HE2 
But I wouldn’t have gone into extreme detail… in the manuscript of course and in the report I would have 
reported but in clear language without dwelling too much on distributions. HE3 
Part of the communication and presentation of results requires conveying concepts of cost-
effectiveness. HE8 discussed how they go about conveying difficult concepts.  
I don’t think there is one way to present things and I’m constantly thinking if somebody doesn’t get it 
there’s a reason. It’s your fault. If people don’t understand what you’ve done then it’s your fault. HE8 
The presentation should be tailored to the mode of communication and the understanding of 
the audience. HE3 produced a more detailed evaluation to be presented to a HTA organisation, but 
that was then shortened to a simplified presentation for a wider clinical audience at conferences.  
If you’ve got a more technical audience you need to give enough of an indication of the technical rigour that 
underlies what you are doing. But that doesn’t necessarily mean you have to report it in a complex way. It’s 
about how you explain things and the level of knowledge that you expect your audience to have. You are 
better off explaining things in less technical language and assume a lower level of knowledge as a general 
rule. If you are talking to a health audience you largely need to focus on the consequences in terms of health 
and clinical aspects and explain and interpret what has happened underneath. And you generally need to 
keep things quite quick and precise. If you are talking to an economic audience you need to provide more 
detail on the exact type of modelling that has been used and more technical detail generally—which would 
be completely lost on a health audience. HE3 
HE1 recommended developing evidence summaries. 
So we have a really nice, easy to read five page summary of the literature and the take home messages… So 
we say this is what we think the literature is saying here are the weaknesses and strengths. This is what it 
would mean for health services. … Taking the difficult evidence and turning it into a simple story. HE1 
HE4 also recommended summaries, but in a video format. 
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I would say the prime output of a cost-effectiveness analysis should be a ninety second video. That should be 
your goal, your prime deliverable. Explaining what happened, why. But you can’t think that’s possible 
when you’ve got a problem. Forget the paper, nobody will read the paper. H4 
Sometimes there are practical issues where presentation formats become unmanageable when 
presented many times for subgroup analyses and intervention comparisons. HE8 criticised the 
overuse of cost-effectiveness acceptability curves—a way of presenting the uncertainty of whether 
an intervention is cost-effective at different cost-effectiveness thresholds.  
They’re a nightmare. Doing an appraisal when you’ve got 15 bloody scenarios and you are looking at 
curves. I mean, they’re not helpful for a decision-making process. What’s much more helpful is to just see a 
table. HE8 
HE8 also preferred summary tables compared with the use of networks of evidence. 
I think networks of evidence is another example. I personally don’t like the diagrams. I understand them 
but I don’t particularly like them. What I want to see as a decision-maker is a table. …. And you can put 
a lot of information in a very simple summary table. HE8 
HE1 and HE2 stressed the need to minimise the complexity of study design. Complex design can 
have the same effect as poor communication—lack of transparency to the decision-maker and 
increased difficulty to understand and use in decision-making. 
When it’s complicated then a decision-maker is not confident enough to change their service around 
something they can’t defend. HE1 
…you want to keep things simple. You don’t want to go into overkill. Because people need to be able to 
understand what you’ve done. HE2 
For HE5, cost of conducting economic evaluations was identified as a barrier at the Local Health 
Authority level but not for the centralised decision-making at NICE. MCDA was successfully used 
as a low cost alternative to conducting a full economic evaluation.  
At the local level—or even in low or middle income countries where there is not enough time and resources 
to do the same things that people do in the UK or in Australia or Canada—MCDA is useful. HE5 
HE4 advocated the use of MCDA for the same purpose; allowing decision-makers to trade 
between timeliness and rigour, whether it is done “…within five minutes, ten minutes, or ten 
weeks”. 
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You choose how much time you are willing to engage with this. MCDA is the only way we can open up the 
decision-making to the ordinary person. So the language and competence is pretty much already there and if 
you make it more complex you are losing them straight away. HE4 
HE3 did not think the clinician’s time to access an economic evaluation was a major factor in 
whether evidence would be used in practice. 
…my general feeling is that if a clinician is interested in something they will access it… My general 
experience is that clinicians working in particular fields are very good at being up to date. HE3 
5.3.2.3 Credibility 
All of the interviewees mentioned the rigour of the economic evaluation in some form; either 
obtaining good quality clinical data, the appropriate methods for economic modelling, or some 
other factor. Seven of the nine participants discussed elements relating to some other aspect of 
credibility, such as the source of the economic evaluation.  
Credibility is necessary in order for the evidence to be “defendable and justifiable”†, and is needed in 
order to make “good, accountable, evidence-based decisions”.‡ Credibility depends on the rigour of the 
methods used; the robustness of the results; expectations about the results; publication in 
academic journals; the level of engagement with clinical experts, decision-makers and other 
stakeholders; the personal characteristics and affiliations of the health economist. 
HE3 described the process of ensuring rigour of the methods for conducting the economic 
evaluation. 
It’s about choosing the appropriate method to address a research question. HE3 
HE7 emphasised the importance of good quality data to ensure rigour. 
It’s about having robust data using large data sets if possible or models that consider all types of evidence to 
avoid selection bias. HE7 
Rigour is required in order to demonstrate cost-effectiveness in a robust manner. HE3 found that 
robust results increase translation into practice. 
I’d think if you’ve got robust results that it’s not cost-effective it would change opinions about whether it 
should be implemented more broadly or supported or extended. Or question why it’s not cost-effective. Or 
revaluate, again. HE3 
                                                     
† HE3 
‡ HE8 
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HE3 found that if the results of an economic evaluation are consistent with expectations the 
findings are more likely to be perceived as credible. 
If findings are against what everyone else expects then everyone else will immediately say “well, is that 
right?” HE3 
HE1 discussed how the credibility of health economists depends on publication in high impact 
journals and receiving large research grants. However, it was noted by HE7 that published 
evaluations, particularly models are more likely to be cost-effective; particularly if they were funded 
by the pharmaceutical or medical device companies. 
We have all these studies coming up of particular things, if it is a model it’s more likely to be cost-
effective… and if its sponsor led then it’s really cost-effective. HE7 
Engagement with clinical experts, decision-makers, and other stakeholders is an important to 
ensure that the right methods are selected. 
Try to involve other experts if needed so that you choose the right method not just one that you would like. I 
often work in teams which brings more than one perspective. HE3 
Personal characteristics of the health economist, including even-handedness, professionalism, 
expertise, and stage of career, can all influence credibility. HE2 advised even-handedness, “I think it 
gains a bit of trust from the different parties that you’ve actually done it from both points of view.” 
HE2 also discussed the importance of the health economist’s professionalism.  
I think being professional about how you deal with people. … I think people get this sense of “oh, is that 
all we are doing?” sometimes. I think they want to feel that they are doing something rigorously and not 
necessarily complicated. …going in with a data collection tool which might just be an excel spreadsheet that 
I have knocked up which breaks things down into categories—as opposed to just sitting and having a chat 
and scribbling in my scruffy notebook and going “oh, is there anything else you can think of”. I think it’s 
about having a process. HE2 
Project management skills are part of professionalism. 
I think the criticisms that come back about the universities are if you think about it more about the manner 
of working than what you are doing. So I think failing to get back to people promptly not sending things 
through when you said you’d send them through. Poor project management, so no one has a clue what is 
going on and when. HE2. 
Another aspect of professionalism is the health economist’s ability to explain their choice of 
methods. When the health economist is able to explain their choices of methods decisions-makers 
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get the sense that they are “…actually working with someone who can add additional expertise and theory to 
their problem that they wouldn’t have necessarily had themselves.” 
HE2 and HE3 discussed the importance of the health economist’s expertise and knowledge of the 
clinical area for building credibility. 
I think it’s good to have done a bit of background reading so that you are not asking really stupid 
questions. HE2 
…Keeping up with the literature in the area. Or doing a literature review in the area to ensure that you are 
working appropriately in the area. HE3 
HE1 wondered whether health economists at later stages in their career might focus more on 
relevance and accessibility rather than pure credibility. 
Ambitious researchers who want to build a CV will be attracted by Lancet. But maybe that’s a stage of 
career thing. Maybe after you’ve built a CV with a hundred papers in in and you’ve got grants then maybe 
you’re not so ambitious to make a name. Then you might want to actually get credit in other ways—trying 
to actually improve health. HE1 
HE1 described an experience where a simple and accessible economic evaluation was seen as not 
credible by a journal reviewer because it was too simple. 
We got a paper back from a journal and one of the reviewer’s comments was this is a rather simple analysis 
as if that was a bad thing and I thought that was a strength. HE1 
Affiliation was a potential source of credibility. 
You need to have a logo that people think is cool. That’s why the consulting firms do well. Because people 
think their logos are cool. They’d say “look, you need to get to this answer and you need to put a logo on the 
report, then we will show it to other people”. HE1 
HE2 discussed how economic evaluations are more likely to have traction if developed as part of 
guidelines or as part of a large report—partly because of increased credibility but also increased 
accessibility. However, HE2 was not sure university affiliation carried weight.  
Because quite often I think there’s this sense of “god you take ages, you’re really slow, you’re really pedantic, 
you communicate things in a way we can’t understand”. There are people who prefer working with a more 
commercial consultancy firm because what they get is more straightforward. And some of them do a good job 
as well. And I think there is also sometimes a sense that you might just go off and do your own thing and 
actually we just want you to do this. HE2 
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5.3.2.4 Summary 
All of the health economists discussed relevance, accessibility, and credibility. Relevance depends 
on the research question, the adaptability of the economic evaluation to specific contexts, and the 
need to consider criteria other than cost-effectiveness. Accessibility depends on the choice of 
language, the complexity of the design, the transparency of the methods and assumptions, the level 
of detail, and whether the communication is tailored to the audience and the mode of delivery. Cost 
and time can also be barriers to accessibility. Credibility depends on methodological rigour, robust 
results that meet expectations, professionalism, external approval through publication or 
affiliations, and engagement with decision-makers, clinical experts, and other stakeholders. Several 
of the health economists pointed out that sometimes trade-offs are required between relevance, 
accessibility and credibility. 
5.3.3 Domain 2: Inner setting 
The inner setting is the structural and cultural context of the organisations the individual decision-
makers work within.140 The structural characteristics are what make up the organisation—how 
centralised the decision-making is in the organisation, the number of individuals in the organisation, 
what groups of individuals are there in the organisation. The cultural characteristics are the norms, 
values, and assumptions of an organisation.228 The networks and communications are the nature 
and quality of the social networks and communications within the organisation and with the health 
economists. Economic evaluations are most likely to have an impact in a culture that values 
efficient use of resources, has evidence-based medicine and the importance of cost-effectiveness as 
assumptions, or has norms regarding use of evidence from economic evaluations. The choice of 
cost-effectiveness threshold was a relevant factor associated with the inner setting that depends on 
both structural characteristics and culture. 
5.3.3.1 Structural characteristics 
Six of the health economists discussed how structural characteristics of the decision-making 
organisation affect how and whether the organisation will use evidence from economic evaluations. 
Four of the health economists mentioned the structural characteristics on three or more occasions 
during the interview. Five of the health economists explicitly discussed the impact of having a 
centralised decision-making group, such as NICE or the PBAC. 
When the decision-making is centralised there can be a direct link between the economic evaluation 
and the decision. If the target audience of an economic evaluation is outside of a group such as 
NICE or the PBAC then translation of evidence from economic evaluations can be more 
challenging. Divided budgets can mean that cost savings are only valued if they are accrued within 
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the internal budget. The societal benefits in health measured by QALYs are not highly relevant to 
organisations such as hospitals in Australia where the focus is more on the business case. 
I don’t think the driver for this one was can we optimise a service. You know, it wasn’t about can we 
improve life and we are prepared to pay more to get better patient outcomes. It was about can we afford to 
do this. [GM: Is it more like a business case?] Yeah. That’s how it was. HE2 
Communication of findings from the economic evaluations is more challenging when the decisions 
are not centralised. 
Because now each of them is their own entity, has their own thing, they don’t really communicate with the 
one down the road, which is very sad. And now some Hospital and Health Services undertake economic 
evaluations—or cost analyses—for certain interventions but the evidence doesn’t get to anywhere else. No 
one else knows. HE9 
There is a distinction between what is useful to an external funding group and what is useful to 
individuals making decisions in healthcare practice. 
… Evaluation adds this extra layer of monitoring and analysis and reporting on top of that which is really 
valuable for people externally but might actually not very important for people who can just see if it is 
working or not working. I think you see it with funding bodies like aid agencies and things when they are 
giving out money to people to implement community disease control programmes and then they are insisting 
on very stringent evaluations of those but the people who are actually doing it there, they are trying to put a 
programme to address a need, and monitor for their own purposes to make sure it is running properly. And 
the evaluation is kind of useful for them but it is more useful for the donor agency for deciding which projects 
they will choose to fund or not.  
There is often not the funding to do economic evaluations at the local level and in low-to-
middle income countries,  
I was involved in looking at local trusts and whether they considered cost-effectiveness evidence, and we asked 
which ones they were implementing and which ones they were not, and we plotted to see if there was a trend. 
And there wasn’t a trend; they were not considering any cost-effectiveness evidence. Because I think at the 
local level, first you don’t have the resources, and then you have to implement it somehow, lack of 
understanding of the cost-effectiveness evidence so lack of reliability of a lot of the cost-effectiveness evidence. 
HE2 
Although MCDA might provide an alternate, cheaper method of incorporating measures 
of cost and effectiveness for decision-making.  
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At the local level—or even in low or middle income countries where there is not enough time and resources 
to do the same things that people do in the UK or in Australia or Canada—MCDA is useful. Thailand 
uses it, and Malaysia, and South Africa. HE5 
5.3.3.2 Culture 
Six of the health economists mentioned the role of culture within the decision-making context. One 
of the health economists explicitly discussed culture on more than two separate occasions.  
Some organisations have cultures that are designed around economic evaluation for decision-
making, such as the PBAC and NICE. 
It’s always quoted that there are some areas where the culture is not amenable to value for money as 
evidence. HE3 
The amenability of cultures using economic evaluation in decision-making differs between different 
clinical areas and evaluation programmes.  
There are some areas where it’s about trying to produce the same patient outcomes but at a low investment 
and other areas where they are much more open to the findings where you actually have to invest more but 
you’ll achieve better outcomes with patients. HE2 
HE9 found that the PBAC was resistant to using probabilistic sensitivity analysis.  
I asked that question of NICE and they said, “Well, we’ll look at that in three years’ time.” The whole 
apparatus is ossified. HE4 
5.3.3.3 Cost-effectiveness threshold 
Four of the health economists identified the cost-effectiveness threshold of decision-makers as an 
important factor. In the Australian context the problem was a lack of a well-defined threshold. 
The big Achilles heel is our floppy threshold. Because the threshold is almost anything you want it to be. It’s 
from zero, which is how the state was running business for a few years. They wouldn’t spend any more 
money to improve health. So their threshold was effectively zero. Only cost saving programs… up to 
$400,000 or $500,000 if you are going to help a child with cancer. So the threshold makes everything a 
bit of a joke because there is no threshold. HE1 
HE4 argued with NICE against using different cost-effectiveness thresholds for different health 
conditions 
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We are simply saying that if you are claiming to be equitable you have to use the same number, whether it is 
about cancer or heart disease. If you change that number—the whole purpose of setting up NICE is to be 
consistent. HE4 
But even if the cost-effectiveness threshold is defined it will result in suboptimal decision-making if 
the threshold is too high, as was argued by HE5 and HE8. 
In some ways there is no point in trying to get the best evidence into practice if you know that the threshold 
is three times higher than it is meant to be. HE5 
It’s also helpful in terms of thinking about whether NICE is doing more harm than good, and what the 
consequences of NICE being pushed to say yes when it should be saying no are. HE8 
The perception of the movable cost-effectiveness threshold was highlighted in discussion of the 
Cancer Drugs Fund in the UK. The Cancer Drugs Fund was singled out by HE8 as a particularly 
inefficient use of resources from a cost-effectiveness perspective, raising the bar for the cost-
effectiveness threshold for cancer drugs. 
The Cancer Drugs Fund is like a blank check and what it demonstrates beyond any shadow of a doubt is 
that there isn’t a blank cheque big enough to fill this hole. HE8 
5.3.3.4 Summary 
The inner setting can be defined by its structural and cultural characteristics. Structural 
characteristics includes the centralisation of decision-making, whether there is funding for 
producing economic evaluations. Cultural characteristics include whether the organisations are 
designed around economic evaluation for decision-making and level of resistance to change. 
Whether an organisation uses a cost-effectiveness threshold and how high a threshold they use can 
be a mix of structural and cultural factors. The nature of the cost-effectiveness threshold affects the 
quality of the decision and the credibility of using evidence from economic evaluations in decision-
making. 
5.3.4 Domain 3: Characteristics of decision-makers 
The third domain of the CFIR-EE is the individual decision-makers who are within the inner 
setting.  
5.3.4.1 Attitudes 
Seven of the health economists discussed decision-makers’ attitudes to economic evaluation. The 
health economists generally found that healthcare decision-makers had some interest in economic 
evaluation. 
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I’ve never had anyone say to look at cost-effectiveness is not good. HE3 
HE3 had heard negative comments from healthcare decision-makers about the hypothetical nature 
of the evaluations. 
I think if people have been trained strongly in evidence-based medicine and levels of clinical evidence, 
sometimes excepting that you might model something not based on randomised controlled trial evidence or 
that you might use preference data based on hypothetical decisions. Those sorts of things, sometimes people 
feel uncomfortable with. HE3 
Individuals will approach evidence—such as evidence from economic evaluations—with their own 
sets of biases, preconceptions and self-interest.  
People don’t respond to evidence rationally. HE1 
HE1 and HE4 found that sometimes evidence from economic evaluation was used to substantiate 
decisions that had already been made.  
If somebody has got to a position based on gut instinct and a bad back of the envelope type of approach, 
which is how most of these things are done and they find a paper that supports that view then they will 
stand squarely behind the paper because it validates their pre-existing position. What I’m trying to say is I 
haven’t actually seen people switch based on a cost-effectiveness study that they weren’t doing. HE1 
At the moment I think NICE are used to saying “we’ve done a thorough economic analysis, here the 
result.” But in most cases I think the decision is taken and it’s judged on whether it supports the case. If it 
doesn’t support the case then it will be rejected. … HE4 
Economic evaluation can be useful for price negotiation, rather than simply a decision-making tool.  
I think the work that we did – we’ve been told at least, the work that we did – helped them in their 
negotiations – the pharmaceutical renegotiations, pharmaceutical price regulation – in some respects 
underpinned the fact that they were able to negotiate a cap on pharmaceutical pricing, so I’m very happy 
with that. HE8 
A factor identified as relevant to positive attitudes about an economic evaluation is the sense of 
ownership. Ownership depends on understanding, credibility, and engagement in the evaluation 
process.  
It’s not ok for them to say “I read this abstract and it seemed like a good idea”. They need to own that 
research and defend their decision. Unless you have done the research yourself it’s really hard to have that 
understanding of the paper. So I think it’s about ownership and it’s about credibility. HE1 
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But I think with the evidence it’s tricky because in some ways the policymakers have to buy in. I think the 
main thing will be to get the policymakers to understand the value of what you are doing and then it will 
come... HE5 
Negative attitudes about outcomes used in economic evaluations can be a barrier. HE6 found that 
clinicians preferred functional outcomes rather than the use of QALYs.  
… They tend to have more confidence in clinical based measures, which are generally validated in their real 
setting. That’s why perhaps quality of life is still a bit controversial or at least less accepted as a meaningful. 
HE6 
If it is something that is outside their familiarity they just frown at it. The functional measures rely more on 
clinical judgement, when confronted with patient reported outcomes they are like “yeah, yeah, yeah… The 
patient only knows so much.” Obviously the patient knows how they feel, but when it comes to reflecting any 
gains the clinicians think the patients aren’t in the best position to know them. HE6 
HE3 identified the risk that decision-makers might have too high an opinion of economic 
evaluation and not be sufficiently critical. 
I think one of the risks of people not understanding all the things underlying cost-effectiveness is that they 
don’t understand weaknesses and limitations and then they are at risk of thinking “well, if something is not 
cost-effective we shouldn’t do it”. HE3 
5.3.4.2 Knowledge 
Four of the health economists discussed decision-makers’ knowledge of economic evaluation as a 
factor.  
Knowledge about economic evaluation and familiarity with methods of economic evaluation 
amongst healthcare decision-makers was seen as variable. Knowledge was highest for centralised 
decision-making groups that explicitly included economic evaluation as part of the decision-making 
process such as NICE and the PBAC.  
They were a group of people who were quite immersed in evidence-based medicine and decision-making 
already. And some of them would have been involved at a state level for different processes. So it would be 
variable. But I’d imagine that the concepts would be understood but the technical details would not as a 
general rule. HE3 
Sometimes there was awareness of terminology but not necessarily detail.  
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Sometimes you have to do a lot of interpretation. Often people they want an economic aspect to their study, 
but they often don’t know the best way to do the economics. It’s so variable because some clinicians have 
done economic evaluations in some way and you’ll meet people who have done none. HE3 
[At NICE] Everyone knows and understands so there is no explanation around what a cost-effectiveness 
acceptability curve is and what a plane is and what a relevant measurement is. They already understood. 
It’s more checking whether the assumptions are valid, and the choice of states in the model, and whether 
anything needs to be done. At the local level there is no… they do lots of other things so they can’t have the 
same level of rigour. They don’t have the same level of process measures or guidelines. HE5 
5.3.5 Domain 4: Outer setting 
The outer setting refers to the economic, political, and social context around the decision to use 
evidence from economic evaluations in healthcare decision-making.140 Factors in the outer setting 
that relate to the use of evidence from economic evaluations in healthcare decision-making include 
funding and healthcare budgets, the incentives of health economists, political influence, current 
practice and the problem of disinvestment, and the media. 
5.3.5.1 Funding and healthcare budgets 
Four of the health economists discussed healthcare budgets and funding for economic evaluations. 
As healthcare budgets tighten there is greater pressure to identify and cease funding for futile 
interventions. HE2 discussed the nature of healthcare budgets with greater constraints on resources 
with the focus of economic evaluation as a way of monitoring and measuring the performance of 
new initiatives.  
On the other hand, economic evaluations require funding. HE7 described the high quality data and 
professional expertise required for a rigorous economic evaluation, but that was only possible 
because their group had “very good funding”. Countries with more funding for conducting economic 
evaluation are also likely to build capacity and specialisation in evaluation.  
I think UK is ahead partly because of methodology. On the MCDA taskforce three of the people from the 
UK run it. So they’re more aware of MCDA in terms of whether they are actually using it or not, I think 
hard to know. There are more discussions around the method. Whether they actually use it it’s hard to say. 
HE4 
A further challenge is the separation between the funding process for healthcare decisions and 
healthcare research decisions. 
So we have approval decisions that don’t take account of the impact on evidence and research, and research 
decisions, which aren’t linked to the decisions that need to be made. HE8 
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5.3.5.2 Incentives of health economists 
Four of the health economists mentioned the incentives of health economists. 
The reward structure for conducting economic evaluations within academia was identified by HE1 
as a potential barrier to the development of relevant and accessible evaluations.  
The way we reward researchers is by numbers of publications and impact factor in journals. If researchers 
were rewarded based on change to health outcomes then I think there’d be quite different research. But I 
think at the moment you get a fellowship if you get into big journals and the route to big journals is not 
necessarily doing useful research; research that can make a huge difference to lots of people. When we moan 
about cost-effectiveness not being used maybe we should look a little bit inwards as well as outwards. HE1 
The reward structure can result in what HE8 described as a “competition of geekiness”. 
We’ve competed ourselves into a geek-hole. “Oh, you’ve missed a bit, and I’ve put that bit in!” Collectively, 
through academic competition, we’ve dived into a completely pointless hole, and missed the real value, which 
is making sure we communicate those principles of what assessments are needed really clearly. HE8 
HE1 observed the same phenomenon. 
We sometimes fall victim to having the fanciest possible modelling approach; hooking on to some big trial; 
tackling an unanswered question so that we can get a really important publication out of it. And we can 
boost our own standing in the community and strengthen our CV have a better chance of getting a 
fellowship; a better chance of getting grants. So maybe we’re selfish in the way we generate research evidence. 
HE1 
Economic evaluations with certain outcomes are more likely to receive publicity. HE7 found that 
the economic burden of disease studies that showed the greatest burden of disease were more likely 
to be picked up and publicly endorsed by advocacy groups. The advocacy groups then prepare 
reports, publish press releases, do media interviews, and engage with politicians. 
HE1 described doing an economic evaluation where the funders were not pleased with the results. 
Before initiating the study, HE1 told the funders, “Please don’t ask us to do a cost-effectiveness study, 
because you won’t like the answer. There’s no way in the world it will be a good answer”. The funders persisted 
even as HE1 told them “We won’t do what you tell us to. We’ll interpret the information as we see it. And it 
won’t be a good story.” After the economic evaluation was produced HE1 told them that “it’s not 
looking good”.  
And they were “how dare you?” They were gobsmacked. The naivety was incredible. I think people see 
health economics as simply something they can control and they’ve just got to get it down, get the right 
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answer and move on. They don’t see us as an objective evaluator. Because cost-effectiveness studies are 
modelling studies, which are in some way discretionary—what evidence you put in, what states you include, 
how you deal with uncertainty—we are so vulnerable to that game being played. HE1 
HE2 had a similar experience working with researchers who were passionate about a healthcare 
intervention that was effective but not necessarily cost-effective. 
I think they are worried that it undermines the evidence that they’ve produced about whether it’s effective. 
It’s still seen as a negative result and not as publishable and not as palatable. A lot of the things that I get 
asked to evaluate have been put in as novel things to meet a perceived demand. So the problem is that you 
turn around and say it wasn’t cost-effective. There’s still a demand, there’s still a need and there is this 
sense of well if we don’t do that what would we do? HE2 
5.3.5.3 Political influence 
Four of the health economists discussed the role of political influence on getting evidence from 
economic evaluations into healthcare practice. HE8 found that politically influence was not always 
apparent from the beginning.  
Having spent a long time going to meetings, workshops, explaining and realising that the problem wasn’t 
the fact that people didn’t understand, the problem was a political one. HE8 
HE8 found that NICE were uninterested when the research “wasn’t giving them an answer they 
felt was politically convenient.” When asked what it would take for a minister to take notice of 
work from a health economist: 
A minister will take notice of our work if a minister thinks that by not taking notice it will create a 
political problem. HE8 
HE8 provided a description of the role of the health economist in relation to organisations such as 
NICE.  
My position has always been that they are the ones who are going to have to stand up and go on the radio 
and take responsibility for what NICE does. And that means that I have to give them the ammunition as 
to why this is right. And I have to do that, not just in a way that I think is academically correct I have to 
do that in a way that they truly buy and own and secondly I have to do it in a way that gives them the way 
of communicating that to a much wider audience. And if as an academic I can’t do that then I can’t 
possibly expect them to go over the parapet into a hail of machine gun fire with no weapons. So it’s not 
enough to have a good idea. That’s not enough. HE8 
HE8 continued. 
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Now if you give them a perfectly good weapon and they still don’t want to go over the top then you have to 
go over the top or find someone else who is willing to go over the top. Then have them shot for cowardice. 
HE8 
5.3.5.4 Current practice and the problem of disinvestment 
Three of the health economists discussed the problem of disinvestment. Politically it is more 
difficult to disinvest than to invest in healthcare services. Often the initial investment required an 
upfront sunk cost. Disinvestment rather than not investing in the first place is also more likely to 
lead to negative public perceptions as people are losing what they already had.  
If it was not cost-effective it’s really hard to think whether it [the economic evaluation] would change 
practice in places at all really. Because then you are in the position where you have to pull out something 
which is in. HE3 
5.3.5.5 Media and public perception 
Three of the health economists discussed the role of the media.  
HE8 had used engagement with the media to make the case of lowering the cost-effectiveness 
threshold. 
Engaging with the media requires preparation and requires the health economist to develop a new 
skillset. 
I’m much more comfortable doing media stuff. But I have to say I don’t like it, there is huge opportunity 
cost. It is exhausting. The most important thing is that journalists understand your position and your work 
and are using that to ask the questions. HE8 
H8 discussed the type of arguments to make 
I go straight to what are the benefits, what is the scale of the benefits, what type of benefits, what do we lose 
elsewhere? What are the opportunity costs—I don’t use the word opportunity cost. What do you get, what 
are you going to have to give up? These are resources that could have been used for other effective 
interventions. And then people say it’s a difficult decision and I say, absolutely, but the key question is the 
discrepancy between the price that’s charged and how much we can afford to pay for the benefits. HE8 
HE8 discussed a potential approach to raising awareness of the opportunity cost of an 
inappropriately high cost-effectiveness threshold through creating a website called “NICE body 
count”. 
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We’ll keep track of the number of patients that NICE decisions have killed in the NHS… It’s a good 
threat. You don’t want to take notice of it but we will. HE8 
5.3.6 Domain 5: Process 
The process of translating evidence from economic evaluation into healthcare practice involves 
multiple stages and the stages are not always linear. Roughly, the process of translating evidence 
from economic evaluation into practice consists of the following six stages.  
5.3.6.1 Scoping and development 
The scoping phase is where the research question is determined and the scope of the study is 
determined. Scoping and development is the earliest stage to determine what trade-offs are required 
in terms of credibility, relevance, and accessibility of the economic evaluation. 
The development stage involves the preparation of the economic evaluation itself. The factor that 
was repeatedly noted as important during scoping and development was the level of engagement 
the health economist had with decision-makers and clinical experts. Many of the elements in 
Section 5.3.2 refer to scoping and development in translating evidence from economic evaluation 
into healthcare practice. 
5.3.6.2 Dissemination 
All of the health economists disseminated their research. There were internal dissemination 
strategies for within the decision-making organisation and external dissemination strategies for a 
wider audience.  
For those working with a centralised decision-making body or HTA organisation, the primary 
methods of internal dissemination—direct to the organisation—were through written reports and 
presentations in person. A few of the health economists had additionally prepared simple summary 
documents. In one case there was two separate reports for the same intervention, one on cost-
effectiveness and the other on budget impact. For some organisations such as NICE and the PBAC 
the format of the reports is standardised.  
They have established guidelines on how to do different things. There are methods on pretty much everything, 
from reviewing, searching through to statistical analysis and sample modelling, mapping and so on. All of it 
has good practice recommendations you need to follow. HE5  
Publication in academic journals was less of a priority for the funders or decision-making groups 
than it was for the health economists. The health economists often had approval for publishing the 
results as part of the contract with these funding organisations. Sometimes the individuals of the 
funding or decision-making groups would also be authors on the paper. Often presentation at the 
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clinical conferences was not done by the health economists themselves but by clinicians involved in 
the study. In one case the economic evaluation was used by a professional organisation to policy 
change at the parliamentary level; it was the professional organisation not the health economist who 
was doing the direct advocacy. One of the evaluations described by the health economists was 
developed for inclusion in a set of clinical practice guidelines, but the economic evaluation was 
published as a separate journal article. The health economist described the attitude of the 
organisation to publishing the findings. 
They didn’t really care if it was published or not. Though I suppose the people doing the guidelines because 
then it backs up the evidence for the evidence base. But in terms of what was going to go into the 
guidelines—yeah they would have gone ahead with or without it with the same recommendations and 
suggestions. I didn’t feel their drive to publish it. …HE2 
HE7 discussed how results from a cost of illness study was publicised and disseminated through 
media channels, and that it lead to a large impact in the attention that the manuscript received 
compared with another cost of illness study that the health economist had written that did not 
receive the same attention. None of the health economists mentioned social media as a 
dissemination strategy.  
5.3.6.3 Deliberation 
For the evaluations developed for centralised decision-making groups the deliberative process in 
each of the cases involved a meeting. For a few of the health economists the role of the economic 
evaluation within these meetings appeared more political than scientific. Sometimes the political 
influence came from the pharmaceutical or medical device companies producing the economic 
evaluation. 
You see this game being played all the time. So a submission comes in, it gets reviewed by the group. They 
pull it to pieces, and then the drug company goes and fiddles with some things and changes it a little bit so 
that it looks better. They just play this stupid game. And then the committee is so bored of it they just say 
yeah go on then. HE1 
Sometimes to HE2 the decisions seemed to be made for the symbolic impact of substantiating 
decisions made for other reasons or conferring legitimacy to the decision-makers themselves. 
Unfortunately I sometimes feel that it’s used to justify a decision rather than make a decision. But I 
suppose that is somewhere on the spectrum of decision-making. HE2 
It’s as much about evaluating a particular thing as about showing that they are an institutional department 
that engages in reflection and evaluation of their own practices and procedures. That seems to mean that they 
are more willing to take on board the findings. HE2 
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5.3.6.4 Monitoring and reflection 
In nearly all of the economic evaluations discussed by the health economists there was no formal 
process to evaluate the impact of the economic evaluation. In some of the instances it was not 
apparently necessarily as the economic evaluation was used directly within a centralised decision-
making process. Otherwise, impact was mostly observed through academic measures, such as 
citations and manuscript views. HE5 developed a web-based cost-effectiveness model that could be 
adapted to local contexts through adapting the parameters to specific contexts. One of the 
advantages of the web-based design was that it allowed observation how many individuals have 
accessed the model. 
5.3.6.5 Engaging 
All of the health economists said that engagement was an important aspect of getting evidence 
from economic evaluation into healthcare practice. Benefits of engagement include improving the 
quality of the economic evaluation, building a relationship with decision-makers, changing 
the attitudes and knowledge of decision-makers, keeping individuals informed of progress of 
the economic evaluation, and an increased sense of ownership leading to a greater likelihood that 
the individuals will become champions of the research. 
Engagement with decision-makers, clinical experts, and stakeholders improves the rigour, 
accessibility, and credibility of the economic evaluation.  
Try to involve other experts if needed so that you choose the right method not just one that you would like. I 
often work in teams, which brings more than one perspective. HE3 
HE1 found that training clinicians to economic evaluations themselves leads to simpler and more 
accessible evaluations.  
So you actually feel like it is a tailored evaluation and not just a churn it out type of evaluation. HE2 
HE3 believes that it is important to involve people who know the current trends in the clinical area-
people who are on the edge of clinical practice “so that they know how things are changing over time… what 
you do now might be completely irrelevant in two years’ time.” 
HE1 described the necessity of engaging with decision-makers in order to build a relationship with 
them.  
You really need to have that relationship and that understanding in place. You can’t just turn up to some 
strangers and say this is what you should do. HE1 
Without engagement with decision-makers the health economists can seem indifferent or careless. 
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Appearing engaged, like bothering to actually have a proper meeting where you sit down with somebody and 
if it’s a service that they are evaluating just understand what that service is and then you can actually ask 
smart questions about it. Rather than thinking what it is and doing something then coming back and 
saying well we didn’t do that. Oh but we’ve also got this person who comes in two days a week and does 
that. Or not knowing where the patients go afterwards and whether it’s supposed to change that or not. 
HE2 
HE1 described how clinicians being engaged in the process can change their attitudes and 
knowledge about economic evaluation. 
You can imagine a clinician learning a lot from that kind of approach and changing the way they think 
about things. So it’s useful to change the way people think about making these decisions. HE1 
Engagement with decision-makers, clinical experts and stakeholders should be maintained 
throughout the process of developing and implementing the economic evaluation so that everyone 
is informed of any progress. 
The way we conducted the research, we had an initial workshop, which included stakeholders and 
academics, we wanted to keep everybody informed as it developed, so over time as we had initial drafts, those 
were circulated to—if you like—this working group. HE8 
When individuals are engaged in developing the economic evaluation they are more likely to feel a 
sense of ownership of the research. 
I drove the writing of the manuscript and all the clinicians at the sites were on the manuscript. So that 
engaged them on the research. And the people from the state government who had been involved in the 
project were also on the manuscript. HE3 
That engagement, understanding and sense of ownership are all required in order to have 
individuals who will champion the research. 
You want to have people on board—crucial to have people on board from practice. So that you’ve got people 
that are interested in that research and champions of that research within the relevant practice or clinical 
area that would be responsible for implementing findings of the research. HE3 
Try to take them on board. Ask them for suggestions, or at least reassure ourselves on what we are doing 
and that they understand. In the end if you try to impose anything from a health economics perspective it 
will be more difficult for them to understand and to encourage any use there. HE6 
The other audience that HE8 engaged with was with pharmaceutical and medical device companies 
(“manufacturers”).  
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Because at the end of the day, actually I don’t think this is a threat. The alternative to this is an 
unsustainable business plan where if you don’t get real about figuring out ways to offer differential pricing 
globally the alternative is much worse. The alternative is that people are basically going to tear up patent 
protection. People are going to reference price, competitive tendering, and we already see it. Middle income 
countries are saying, “Hold on a minute, we’re not so bothered about your intellectual property, we’re going 
to licence a generic manufacturer for your branded product. And if you don’t like it, what are you going to 
get us through the WTO? Well, the world has changed. You’re the ones with the begging bowl and asking 
us to lend you money to sustain your budget deficit not the other way around. So I think manufacturers, 
there’s some manufacturers I know realise that getting real and having predictable evidence-based prices is in 
the long haul a much better option. HE8 
5.4 DISCUSSION 
The views from the health economists interviewed were consistent with the CFIR-EE. The health 
economists addressed each of the domains within the framework. The most frequently addressed 
and most detailed domain was the characteristics of the economic evaluation. The economic 
evaluation needs to be answering a practice relevant question using data that is high quality and 
applicable to the decision-making setting. Communicating the evidence from economic evaluations 
was seen as a challenge of finding the correct choice of language and level of detail for the target 
audience. The credibility of the economic evaluation does not only depend on the quality of the 
methods used and whether it is published in a prestigious journal, but was also seen to depend on 
the health economist themselves and their affiliations, personality, and relationship to the decision-
maker. 
The health economists interviewed were rarely the people who would publicise and advocate 
change in practice based on the results of the economic evaluation. Rather, advocacy was primarily 
the responsibility of the funder of the economic evaluation. Funder-led advocacy was successful 
when the results of the economic evaluations aligned with the interests of the funder. However, in 
cases where a large scale intervention programme was shown to not be cost-effective or the 
economic burden of a disease of interest was shown to be less than previously established then the 
funder did not actively publicise, advocate or otherwise implement the research. Although, in the 
examples discussed the funders did not interfere with publishing the results as publication was 
stipulated in the contract between the funder and the health economist.  
In the absence of an alternative funding model for economic evaluations, the health economist 
needs to become their own advocate. They need to, as one health economist said, “Go over the 
parapet” and argue the case for change in the media and with stakeholders. Health economists 
recommended bringing clinical experts on board and giving the clinical experts a sense of 
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understanding or ownership of the research such that the clinical experts become advocates for the 
research. 
The health economists identified determinants of translation that were not identified in earlier 
studies. Such as the importance of professionalism, the inconvenience of certain methods of 
presenting evidence in large documents, and the use of inappropriate or ill-defined cost-
effectiveness threshold. The importance of communication and engaging with stakeholders and 
clinical experts was a common theme for all of the health economists interviewed as had been 
emphasised previously in published interviews and surveys of healthcare decision-makers. 
The less centralised the decision-making process, the harder it was for the health economists to 
translate evidence from economic evaluation into healthcare practice. In a less centralised context 
there are greater gains to be had in engaging with clinicians at all stages of the process, thoughtful 
dissemination, and implementation targeted at barriers to behavioural change. 
The experiences of the health economists interviewed will differ from health economists of other 
backgrounds. Health economists from the North America, Europe or Asia would have very 
different experiences, as would health economists working in developing countries. All of the 
health economists interviewed were academic rather than from consultancies or from the 
pharmaceutical or medical device companies. Further research into the experiences of health 
economists from the pharmaceutical or medical device industry would provide greater insight into 
the many challenges of translating evidence from economic evaluation into healthcare practice. 
The inner setting was particularly identified as a relevant factor in the interviews with health 
economists. It has been less of a focus in the published interviews and surveys of healthcare 
decision-makers because the inner setting was framed as a constant. The most relevant structural 
characteristic of the inner setting determining the use of evidence from economic evaluations is the 
level of centralisation. Translating evidence from economic evaluations into healthcare practice can 
be straightforward for a centralised decision-making group with an established culture of using 
evidence from economic evaluations in decision-making, although some of the health economists 
interviewed found it hard to change suboptimal process within centralised inner settings. 
Within the inner setting, the attitudes and knowledge about economic evaluation of individual 
decision-makers influences how likely they are to use evidence from economic evaluations in 
decision-making. The influence of decision-maker knowledge of economic evaluation on 
translation is why the health economists and the healthcare decision-makers considered engaging 
with all relevant stakeholders from an early stage in the economic evaluation to be crucial. Engaging 
early can provide a sense of ownership of the research, so decision-makers feel more confident of 
the methods and more likely to champion the findings. 
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The health economists and the healthcare decision-makers identified many of the same features of 
the outer setting relevant for translating evidence from economic evaluation into healthcare 
practice. Outer setting determinants of translation included funding for healthcare budgets and 
health service research funding, political and media influence, and challenges with disinvesting in 
current practice. Additionally, the health economists identified the academic incentives that they 
face and how the incentives are misaligned the needs of healthcare professionals and policymakers. 
The approach to economic evaluation of using a single figure to inform a decision—whether an 
ICER or net monetary benefits—is challenged by alternative approaches such as MCDA. There 
were several cases described by the health economists of healthcare decision makers valuing being 
able to consider multiple decision criteria. How the challenges of translating MCDA compare with 
economic evaluation is not known. 
Further research should empirically assess the strategies identified by the health economists. The 
CFIR-EE provides a method of categorising strategies for facilitating translation. Methods will need 
to be developed to measure factors such as engagement, communication, and advocacy when 
applied to economic evaluation.  
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6 SYNTHESIS AND DISCUSSION 
6.1 SUMMARY OF FINDINGS 
The thesis used novel methods to explore the translation of evidence from economic evaluations 
into healthcare policy, including (1) the development of the CFIR-EE; (2) applying discrete choice 
experiment methods to evidence from economic evaluations; and (3) interviewing health 
economists about their experiences translating evidence from economic evaluations into healthcare 
policy and practice. 
Study 1 involved a review of previous research assessing the barriers and facilitators to using 
evidence from economic evaluation in healthcare decision-making, and mapped the barriers and 
facilitators to the CFIR, resulting in the CFIR-EE, which forms the theoretical framework for the 
thesis (Figure 11). 
Figure 11 CFIR-EE 
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Framework does not distinguish between characteristics relevant to the economic evaluation and 
characteristics relevant to the healthcare decision-makers, the context (inner or outer), or the 
process of implementation. The Accessibility-Acceptability Framework informed the three 
constructs used within the characteristics of the economic evaluation domain—relevance, 
accessibility, and credibility. 
In Study 2, the discrete choice experiment measured decision-maker’s preferences and the trade-
off they were willing to make between the characteristics of the economic evaluation—relevance, 
accessibility, and credibility. The attributes the make up the credibility, accessibility and relevance of 
an economic evaluation were not dominantly preferred. The decision-makers were willing to trade-
off between the three aspects of credibility, accessibility and relevance. The development of an 
economic evaluation should therefore consider what trade-offs between credibility, accessibility and 
relevance will be most preferred for the target audience of the economic evaluation. Considering 
such trade-offs does not necessarily require conducting a full discrete choice experiment for every 
situation rather a few more exploratory qualitative questions provide the researchers with an 
indication of what criteria are likely to be of importance in any given situation. 
The discrete choice experiment represents the first use of this method for measuring the 
preferences for a decision-making tool. The discrete choice experiment is a useful tool for 
discerning which attributes matter most and what trade-offs are possible. The healthcare decision-
makers had a clear preference for a good quality economic evaluation that is specifically applicable 
and communicated well be an independent researcher. The findings from the discrete choice 
experiment indicate that health economists should aim for high quality methods whilst also 
ensuring that the findings from economic evaluations are communicated well. The decision-makers 
surveyed using the discrete choice experiment were willing to wait for good quality research that 
they could understand and trust. 
The interviews (Study 3) are the first qualitative investigation into the translation of evidence from 
economic evaluation into healthcare policy and practice from the perspective of the health 
economists producing the evidence. The health economist perspective provides essential insight 
into the factors relevant to the five domains of the CFIR-EE—characteristics of the economic 
evaluation, inner setting, characteristics of decision-makers, outer setting, and process.  
In the interviews with the health economists and the literature review, the factors most commonly 
mentioned as being relevant to translating evidence from economic evaluation were the 
characteristics of the economic evaluation—accessibility, credibility, and relevance—as well as 
the need to engage with decision-makers, clinical experts and other stakeholders. Relevance of the 
economic evaluation depends on the research question, the outcomes assessed, and the adaptability 
of the evaluation. Accessibility depends on timeliness, complexity of study design, choice of 
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language, transparency, level of detail, and tailoring presentation to mode of communication. 
Credibility of an economic evaluation depends on the rigour of the methods, robustness of the 
results and whether the results match expectations. Engagement with decision-makers was viewed 
as improving relevance, credibility, and accessibility and improving the ability to trade between 
those characteristics. Engagement was seen to be part of the process of encouraging decision-
makers, clinical experts and other stakeholders to feel ownership of the research and become 
comfortable with the research and or even champion the research. 
6.2 FINDINGS BY STAGE OF IMPLEMENTATION PROCESS  
The following section syntheses the findings from the thesis into strategies to facilitate the 
translation of evidence from economic evaluation. The strategies were recommended by healthcare 
decision-makers from qualitative studies in the literature (Study 1), are reflective of the preferences 
of decision-makers found in the discrete choice experiment (Study 2), or were used by health 
economists to translate their own research into healthcare policy or practice (Study 3). 
The strategies are organised by when they occur within the five stages of the CFIR-EE 





 Monitoring and reflection 
 
6.2.1 Stage 1: Scoping 
The scoping stage is where the research question and the scope of the evaluation are determined—
including the time, resources, and expertise required. Scoping is the earliest stage to determine what 
trade-offs are required in terms of the credibility, relevance, and accessibility of the economic 
evaluation.  
The strategies during the scoping stage will be depend on whether the economic evaluation was 
initiated by a health economist or whether the research team enlists the expertise of a health 
economist. If the economic evaluation is health economist initiated then the health economist will 
need to engage with decision-makers, clinical experts and other stakeholders in order to determine 
the practice relevance of the research question, the outcomes to be assessed in the economic 
evaluation, what training is required, time constraints, and whether methods such as budget impact 
analysis, equity analysis, or MCDA are appropriate.  
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The majority of the strategies in Table 14 were identified in both the literature review of barriers 
and facilitators to using evidence from economic evaluations as well as the interviews with health 
economists.  
Table 14 Implementation strategies to facilitate the translation of evidence from economic 









Develop a practice relevant research question X  X 270 
Engage with decision-makers X  X 270 
Confirm the practice relevance of the outcomes to be assessed in the 
economic evaluation X  X 
270 
Determine what training is required for the decision-makers, clinical 
experts, health economists, or other stakeholders. X  X  
Determine the appropriate timeframe for the development of the 
economic evaluation X X X  
Determine whether budget impact analysis or equity analysis is 
appropriate X X X  
Determine method of balancing multiple decision criteria (if 
appropriate)  X  X  
 DCE, discrete choice experiment; HE, health economist; MCDA, multiple-criteria decision analysis 
There were seven strategies identified that were relevant for the scoping stage. Three of the 
strategies are well established in the implementation science literature270 and were confirmed with 
the literature review of barriers and facilitators to using evidence from economic evaluation (Study 
1) and the interviews with health economists about their experiences translating evidence from 
economic evaluation into healthcare policy and practice (Study 3). 
1. Develop a practice relevant research question. The economic evaluations that 
addressed practice relevant questions were seen as more likely to be taken up and used to 
address real world problems. 
2. Engage with decision-makers. Engagement was described as one of the most important 
elements for making sure that the research question and the methods used are relevant, 
that the health economist has credibility to the healthcare decision-maker, and for 
improving accessibility by involving decisions in the evaluation process. The decision-
makers include health professionals and policymakers and other stakeholders. 
3. Confirm the practice relevance of the outcomes to be assessed in the economic 
evaluation. Choice of health and cost outcomes should be tailored to the needs of the 
relevant healthcare decision-makers. Choices regarding health and cost outcomes include 
whether to measure health outcomes in terms clinical measures (e.g. life-years gained), 
health utility measures (e.g. QALYs), or valuing health outcomes monetarily. Similarly, the 
perspective chosen for measuring costs should be relevant to the healthcare decision-
makers. 
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The other strategies were specifically pertinent to the translation of evidence from economic 
evaluation, and were identified through the literature review, the discrete choice experiment, and 
the interviews with health economists. The strategies were not from the broader implementation 
literature.  
4. Determine what training is required for decision-makers, clinical experts, health 
economists, or other stakeholders. Determining training requirements is relevant for 
other types of research but is particularly relevant for economic evaluation because 
economic evaluation has a substantial researcher-clinician knowledge gap. 
5. Determine the appropriate timeframe for the development of the economic 
evaluation. Healthcare decision-makers and health economists found that there are 
windows of opportunity where evidence can have an impact on healthcare decision-
making. Some respondents recommended considering the importance of timeframe in the 
scoping process, particularly with regard to tailoring the level of complexity of the 
economic evaluation. The discrete choice experiment found that healthcare decision-
makers were willing to wait for good quality research, but timeliness was valued. 
6. Determine whether budget impact analysis or equity analysis is appropriate. A 
common comment in interviews and surveys with healthcare decision-makers in the 
literature and the interviews with health economists was that cost-effectiveness is useful for 
healthcare decision-making, but often not sufficient. The scoping should determine 
whether other decision-making criteria be considered as part of the evaluation process. The 
discrete choice experiment found a preference for economic evaluations that provided an 
analysis of equity impact but not for economic evaluations that mention potential equity 
impact compared with not discussing equity at all. 
7. Determine the method for balancing multiple decision criteria. If decision criteria 
other than cost-effectiveness are going to be included in the economic evaluation—such as 
budget impact or equity impact—then the scoping should determine the approaching to 
balancing competing criteria. MCDA was a method discussed in the interviews with health 
economists.  
6.2.2 Stage 2: Development 
The development stage is when the economic evaluation is prepared (Table 15). The development 
stage includes data collection, economic modelling, and writing up the results. For a trial-based 
economic evaluation the development stage would include both the trial itself as well as the analysis 
of the costs and health outcomes after the trial is completed.  
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Table 15 Implementation strategies to facilitate the translation of evidence from economic 









Seek contributions and feedback from clinical experts and other 
stakeholders X  X 
270 
Follow good practice guidelines for data collection and analysis X X X  
Avoid unnecessarily complex methods X X X  
DCE, discrete choice experiment; HE, health economist 
 
There were three strategies identified as relevant at the development stage.  
1. Seek contributions and feedback from clinical experts and other stakeholders. The 
importance of seeking contribution and feedback is well established in the implementation 
science literature and was confirmed in the literature review of barriers to using evidence 
from economic evaluations and the interviews with health economists. Similar to the 
importance of engagement during the scoping phase, the contributions improve the 
relevance, credibility, and accessibility of the economic evaluation. 
2. Follow good practice guidelines for data collection and analysis. The importance of 
using good quality data in an economic evaluation and following best practice for 
developing models was raised by both healthcare decision-makers and in the interviews 
with health economists. The discrete choice experiment found that, for healthcare 
decision-makers, good quality methods for economic modelling and good quality data 
informing the model are two of the most prioritised attributes of an economic evaluation. 
3. Avoid unnecessarily complex methods. The counterpoint to the importance of using 
good quality methods for economic evaluation is that the more complex the economic 
evaluation is then the less it is accessible to healthcare decision-makers. Complexity as a 
barrier to using evidence from economic evaluation in healthcare decision-making was 
identified in the literature review, the interviews with health economists. It is through the 
contribution and feedback from the clinical experts and other stakeholders that the correct 
balance between rigour and complexity will be met. 
6.2.3 Stage 3: Dissemination  
The dissemination stage refers to the publication and presentation of the findings from the 
economic evaluation. The findings from the barriers and facilitators literature review, the discrete 
choice experiment, and the health economist interviews all emphasise the importance of 
communication (Table 16).  
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Dissemination involves directly presenting the results to a decision-making committee through a 
report or in person, publishing in journals, conference presentations, press releases, media 
interviews, or publishing online or through social media.  
Table 16 Implementation strategies to facilitate the translation of evidence from economic 









Tailor presentation and language to audience X X X 271 
Ensure transparency in the communication of assumptions and 
results X X X  
Prepare evidence summaries X  X  
Report conflicts of interest X X   
Determine the ways the analysis can be adapted to specific contexts   X  
Consider adaptable online model   X  
Determine and enact media strategy   X  
DCE, discrete choice experiment; HE, health economist 
The discrete choice experiment found that good communication was one of the most highly valued 
aspects of an economic evaluation by healthcare decision-makers. The literature of healthcare 
decision-makers perceived barriers and facilitators to using economic evaluation and the interviews 
with health economists identified strategies to improve dissemination. 
1. Tailor presentation and language to audience. The importance of determining the 
appropriate audience and tailoring the presentation, including choice of language, for the 
research is a well-established principle in implementation science271 and was identified as 
important by both healthcare decision-makers and health economists. Technical language 
is a commonly cited barrier to understanding evidence from economic evaluations. 
2.  Ensure transparency in the communication of assumptions and results. Both 
healthcare decision-makers and the health economists interviewed emphasised the 
importance of transparency of the assumptions of an economic evaluation. If the 
assumptions are not transparent then the credibility of the evaluation cannot be assessed 
by the healthcare decision-maker. 
3. Prepare evidence summaries. Evidence summaries were seen by healthcare decision-
makers and health economists as improving the accessibility of economic evaluations by 
being shorter than full economic evaluations and only providing the most relevant 
information.  
4. Report conflicts of interest. To healthcare decision-makers, the credibility of economic 
evaluations has been damaged by the number of studies produced by pharmaceutical and 
medical device companies. In the discrete choice experiment, healthcare decision-makers 
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significantly preferred economic evaluations produced by health economists that did not 
have conflicts of interest. 
Furthermore, the interviews with health economists identified factors relevant for dissemination 
that had not been reported by healthcare decision-makers in earlier studies. 
5. Determine the ways the analysis can be adapted to specific contexts. The health 
economists found that in certain situations it is necessary to adapt economic evaluations in 
different contexts. The examples given were adapting economic evaluations to reflects 
differences in costs and clinical epidemiology between different hospitals and different 
local areas within a country. 
6. Consider adaptable online model. A facilitator for improving the relevance of 
economic evaluations identified by one health economist was the use of adaptable online 
models. Adaptable models allow healthcare decision-makers to adjust the parameters (the 
inputs) of the model to reflect local conditions. So the decision-maker does not have to 
rely on an evaluation using costs or other parameters from a different setting. By having 
the model online it can be easily accessed and use can be monitored (see Section 6.2.5). 
7. Determine and enact media strategy. The model put forward by one of the health 
economists was that the role of the economic evaluation was primarily as support for 
good decision-making. But it can become the role of the health economist to “go over the 
parapet” and directly engage in a media strategy to change public perceptions.  
6.2.4 Stage 4: Deliberation 
Deliberation is the stage where the evidence from the economic evaluation is used for decision-
making (Table 17), which assumes that dissemination was successful and the decision-makers 
within the internal context are using the economic evaluation. The health economists interviewed 
stressed the importance of an appropriate cost-effectiveness threshold—so that the decision to say 
whether an intervention is cost-effective is representative of the opportunity cost. Both healthcare 
decision-makers and health economists highlighted the need to involve relevant stakeholders at the 
deliberation stage. 
Table 17 Implementation strategies to facilitate the translation of evidence from economic 









Involving relevant stakeholders X  X  
Selecting the cost-effectiveness threshold   X  
DCE, discrete choice experiment; HE, health economist 
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6.2.5 Stage 5: Monitoring and reflection 
Monitoring and reflection on the impact of the economic evaluation was not a commonly reported 
part of the process of developing an economic evaluation either from the perspective of the 
healthcare decision-makers or the health economists (Table 18). However, monitoring and 
reflection of impact is a recommended strategy for other forms of evidence used in healthcare 
decision-making, such as clinical practice guidelines.271 The difference in emphasis between 
economic evaluations and clinical practice guidelines with regard to monitoring and reflection is a 
result of the greater emphasis on guiding change in practice within the field of clinical practice.   
Table 18 Implementation strategies to facilitate the translation of evidence from economic 









Plan for monitoring and reflecting on impact of the economic 
evaluation   X 
271 
DCE, discrete choice experiment; HE, health economist 
6.3 DISCUSSION 
In bringing together the studies described in the thesis and the synthesis within this chapter there 
are two primary implications for understanding the translation of evidence from economic 
evaluation into healthcare policy and practice: 
 The first implication is that economic evaluation needs to be considered in the broader 
implementation context. It is not sufficient to publish an economic evaluation and hope that it 
translates into healthcare policy or practice. The process of developing an economic evaluation and 
communicating the results needs to include an awareness of the needs and preferences of 
healthcare decision-makers and the context in which they work. 
The other implication is that implementing evidence from economic evaluation is different to 
implementing other innovations, and involves unique challenges. Economic evaluation is a 
type of research specifically designed to inform a decision—the results of an economic evaluation 
are specific to a decision-making context and are not generalisable to other contexts. The language 
and theoretical basis can be unfamiliar to health professionals. Economic evaluations are designed 
for decision-making at the population level, so implementation at the individual clinician level is 
lacking. 
The CFIR-EE contextualises the translation of evidence from economic evaluation into a broader 
implementation framework, while addressing the features of economic evaluation that make it 
unique as an innovation. Using the CFIR-EE has implications for identifying barriers to using 
evidence from economic evaluation and for developing strategies to facilitate translation. The 
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CFIR-EE enables deeper analysis of determinants of translation from economic evaluation into 
healthcare policy and practice. Barriers to using evidence from economic evaluation can be 
categorised into the five CFIR-EE domains, clarifying the nature of the barriers and how the 
barriers interact. The CFIR-EE can also be used in the development of strategies to facilitate 
translation by targeting the strategies to domains or constructs within domains with the recognition 
of likely interactions between domains. Future evaluations of strategies can be used to categorise 
and compare the effectiveness of strategies targeting different CFIR-EE domains, different stages 
of the implementation process, or the different constructs that define the characteristics of the 
economic evaluation itself. 
The synthesis in this chapter presents an example of the use of the CFIR-EE to characterise 
implementation strategies for evidence from economic evaluations. In the synthesis, the strategies 
to facilitate translation identified by healthcare decision-makers and health economists are 
categorised into the five stages of the process of implementation domain of the CFIR-EE.  
Strategies that were particularly emphasised by the health economists that were interviewed include: 
(1) engagement with stakeholders and clinical experts; (2) communication and presentation of 
findings; and (3) health economist led advocacy.  
Health economist engagement with stakeholders and clinical experts can occur at all stages within 
the process domain of the CFIR-EE, and were seen as crucial to improving the relevance, 
accessibility, and credibility of the economic evaluation. Health economists experienced the benefits 
of having stakeholders and clinical experts involved through the process of scoping, developing, 
and disseminating the economic evaluation in terms of ensuring that the economic evaluation 
addresses a practice relevant research question, improved stakeholder understanding of economic 
evaluation methods, and increased stakeholder belief in the health economist themselves.   
Appropriate communication and presentation of findings is a factor that has been shown to be 
highly relevant in all of the studies discussed in the thesis. Poor communication from health 
economists was one of the most commonly cited barriers to using evidence from economic 
evaluation in the studies included in the systematic review and was consistent with the findings 
from both the discrete choice experiment and the interviews with health economists. The discrete 
choice experiment found that decision-makers and a strong preference for good communication 
from health economists. In the health economist interviews, the importance of good 
communication was one of the most commonly discussed factors for translating evidence from 
economic evaluations into health policy and practice. The health economists discussed the necessity 
for economic evaluations to use the language and level of detail appropriate for the audience of the 
economic evaluation and tailoring the presentation of findings to different audiences. 
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A key finding from the interviews with health economists was that there are times where the health 
economist needs to become an advocate for change, particularly in situations where the findings are 
inconvenient to the organisation that originally funded the research. In many of the example 
economic evaluations described by the health economist it was the funding organisation’s 
responsibility to publicise the findings and advocate change based on the results of the economic 
evaluation. The problem with funder-driven implementation is that the level of support can depend 
on whether the results of the economic evaluation align with the interests of the funding 
organisation. The health economists described situations where the funder lost interest in the 
findings from economic evaluations when the results were not as expected and did not pursue usual 
funder-led advocacy. In the absence of funder-led advocacy, the health economist is left alone to 
engage with the media and with individual stakeholders to argue for the case of change. 
6.3.1 Limitations 
It is difficult to distinguish between research that has a symbolic impact compared with research 
that has an instrumental impact. If the purpose of economic evaluation is purely to signal 
legitimacy, than this is not research translation. Although some of the health economists 
interviewed provided examples where their research translated into healthcare policy or practice, it 
was not possible to demonstrate whether the economic evaluation drove decision making. Both 
researchers and healthcare decision makers have incentives to signal that research is having an 
instrumental impact rather than a symbolic impact, making an instrumental impact harder to detect. 
Further case study analysis, including document analysis and observation of decision-making 
processes, is required to positively determine whether evidence from economic evaluation is having 
an instrumental impact on healthcare decision making.  
It is difficult to judge the relevance of the CFIR-EE constructs based on how well they are 
represented in the literature review (Section 2) or in the interviews (Section 5). Respondents were 
asked specifically about their views and experiences with economic evaluation and are therefore 
primed to consider factors that fit within the characteristics of the economic evaluation domain 
rather than contextual, interpersonal, or procedural factors. 
The thesis emphasises the values and beliefs of health economists and health researchers and their 
experiences translating evidence into healthcare policy and practice. The interviews were only 
conducted with health economists and about 40% of the discrete choice experiment respondents 
were health researchers. This perspective influences the findings of the research; however it is 
balanced by the previously published literature in this area, which had largely ignored the 
perspectives of health economists and health researchers. 
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The interviews were only conducted in Australia and the UK and the majority of the discrete choice 
experiment responses were from Australia. This, along with sample size limits the generalisability of 
the findings. Experiences are likely to be very different in the USA, where economic evaluation 
plays a less central role, or in developing countries where there are greater resource constraints.  
Neither the research conducted as part of the thesis nor the published literature compares the 
translation of evidence from economic evaluation with other types of evidence. Many of the factors 
relevant for the translation of evidence from economic evaluation will be relevant to other types of 
evidence. However, by focussing specifically on economic evaluation it is possible to discuss 
specific technical details relevant to economic evaluation including willingness to pay for health and 
MCDA.  
6.3.2 Implications and Future research 
The CFIR-EE can be used to guide future research examining the translation of evidence from 
economic evaluation into healthcare policy and practice by providing a framework to categorise 
barriers and facilitators to translation. By categorising barriers and facilitators into domains the 
CFIR-EE provides a systematic approach to assess how the barriers and facilitators interact. Under 
the CFIR-EE, barriers and facilitators are characterised by whether they reflect characteristics of 
the economic evaluation itself or the knowledge and attitudes of the healthcare decision-makers, 
the structure and culture of the organisation the decision-makers work in, or the incentives and 
community attitudes the organisation faces. The CFIR-EE was based on evidence from studies 
investigating the barriers and facilitators to translating evidence from economic evaluation. The 
adaptation did not consider factors relating to other types of evidence. It remains to be seen what 
would be the nature of an adaptation of the CFIR for translation of other study designs. 
The discrete choice experiment was based on a single scenario where evidence from economic 
evaluations are used in decision-making—the decision to purchase a piece of hospital equipment. 
However, preferences for the design and communication of evidence from economic evaluation 
might be different for different types of decision and in different settings. Preferences for including 
equity analysis might be greater in scenarios where fairness and distributional concerns are more 
apparent, such as an economic evaluation of the Royal Flying Doctor Service. Preferences for 
quality and communication might be different in settings where economic evaluation is an 
established part of the process, such as the PBAC or NICE. Discrete choice experiments could also 
be used to measure preferences for other types of evidence and instruments used for decision-
making—such as MCDA or budget impact analysis. 
Further research is warranted into the perspectives of health economists—and researchers more 
generally—and their experiences translating evidence into healthcare policy and practice. The 
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experiences of health economists from other settings—such as from industry or from countries 
other than Australia and the UK—might vary. The challenge of translating evidence from 
economic evaluation in low- and middle-income countries was not explored in the thesis and has 
been neglected in the literature. The constraints faced by health economists in such countries and 
the difficulties translating evidence into healthcare policy and practice is likely to be greater than in 
Australia or the UK. There is no research comparing the challenges that health economists face in 
translation to the challenges faced by other researchers translating evidence into practice. Such 
comparative research would provide insight into how implementation strategies should vary based 
on the type of evidence. 
The role knowledge brokers may play in translating evidence from economic evaluation into 
healthcare policy and practice remains poorly defined. The “going over the parapet” metaphor used 
by the health economist assumes that the translational activity must be by the health economist 
themselves and not a third party knowledge broker or implementation specialist. 
Different settings required different approaches to translating evidence from economic evaluations. 
The optimal approach also depends on the funding available for evaluation. Some of the health 
economists’ interviewed found that MCDA can be useful where there is limited resource for 
evaluation. 
The unique challenges of translating evidence from economic evaluation into healthcare policy and 
practice point to the need for best practice implementation guidelines for health economists. This 
thesis provides the evidence basis for future efforts to develop guidelines for translating evidence 
from economic evaluation into healthcare policy and practice. Such guidelines should incorporate 
the strategies described in the synthesis within this chapter. The development of such guidelines 
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7 CONCLUSION 
Multiple methods were used to understand the translation of evidence from economic evaluation 
into healthcare policy and practice. Study 1 identified the barriers and facilitators to using evidence 
from economic evaluation in healthcare decision-making and used those to develop the CFIR-EE. 
Study 2 measured the preferences of decision-makers for evidence from economic evaluation. 
Study 3 gathered the views and experiences of health economists on translating evidence from 
economic evaluation into healthcare policy and practice. 
The CFIR-EE provides a framework for further qualitative research into the determinants of 
translating evidence from economic evaluation into healthcare policy and practice, and the 
development of implementation strategies specific for evidence from economic evaluations. The 
framework has been used in this thesis to identify evidence gaps in the literature, such as the limited 
barriers and facilitators relating to the outer setting domain or the implementation process domain. 
The framework has also been used to discuss the relationships between barriers and facilitators 
such as the synthesis (Section 6.2), which categorised strategies to translate evidence from 
economic evaluation that were often characteristics of the economic evaluation into stages of the 
process domain.  
The discrete choice experiment represents the first use of this method to measure the preferences 
of decision-makers for evidence from economic evaluations. The attributes and levels were 
designed to reflect the constraints of producing an economic evaluation and the factors that need 
to be balanced to translate the results into healthcare practice. The discrete choice experiment 
found that decision-makers’ preferences between credibility, acceptability and relevance are not 
dominant—the decision-makers were willing to trade between the attributes representing the 
constructs. Decision-makers had different preference profiles for the attributes within the discrete 
choice experiment. The decision-makers wanted a health economist who was good at modelling 
and communication, but fair modelling and communication was seen as no better than poor quality 
communication and modelling. In contrast, decision makers preferred fair levels over poor and 
good levels over fair for the clinical evidence and applicability attributes. In some cases the 
decision-makers were willing to wait at least a year for good quality research.  
The activities involved in translating evidence from economic evaluations into healthcare practice 
have been outlined. The step most emphasised by both the health economists in the interviews and 
the healthcare decision-makers in the literature review was the importance of engaging appropriate 
individuals in the economic evaluation process at all stages. Benefits of engagement included 
improving the quality of the economic evaluation, building a relationship with decision-making, 
changing attitudes and knowledge of decision-makers, keeping individuals informed of progress, 
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and an increased sense of ownership leading to a greater likelihood that the individuals will become 
champions of the research. 
To translate evidence from economic evaluation into healthcare process it is necessary at each stage 
of the process to find the correct balance between credibility, accessibility, and relevance taking into 
account the inner and outer setting and knowledge and attitudes of the decision-makers. To 
increase the impact of economic evaluation on policy, health economists need to engage with 
policymakers, healthcare professionals, and the community; communicate findings in a manner 
appropriate to the audience and mode of communication; and advocate for the best practice use of 
economic evaluation in healthcare decision-making.  All of this takes time, planning and resources 
as well as a strong desire to take leadership and action—sometimes with little institutional support. 
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APPENDIX B: PRELIMINARY SURVEY TO DETERMINE 
ATTRIBUTES AND LEVELS 
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 Cost Effectiveness Evidence and Infection Control Decision Making 
1. Are you?
An infectious disease physician
An infection control practitioner
Neither
2. What is your gender
Female
Male
Other (please specify) …………………………………………………………………………………………….. 
3. How many years have you worked in healthcare? ………………………………………………
4. Have you received any training in cost effectiveness or economic evaluation?
No
Yes (please specify) ……………………………………………………………………………………………… 
Section 1: Factors that influence use of evidence 
1. Below are a number of factors that have been shown to influence whether cost effectiveness
evidence is used in healthcare decision making. We are interested in how important these factors
are to you if you were considering using evidence from a cost effectiveness study in your decision
making within the context of infection control.









Quality of clinical evidence 
informing the cost 
effectiveness study 
1 2 3 4 5 
Rigour of methodology used 
to estimate cost effectiveness 1 2 3 4 5
Length of time required to 
conduct the cost 
effectiveness study 
1 2 3 4 5 
Making cost effectiveness 
studies easier to understand 1 2 3 4 5
Professional training in cost 
effectiveness 1 2 3 4 5 
Considering equity effects 
of healthcare interventions 
in cost effectiveness studies 
1 2 3 4 5
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Considering budget impact 
of healthcare interventions 
in cost effectiveness studies 
1 2 3 4 5 
Considering clinical need of 
healthcare interventions in 
cost effectiveness studies 
1 2 3 4 5 
Avoiding conflicts of 
interest (e.g. studies funded 
by pharmaceutical or 
medical device companies) 
1 2 3 4 5 
Using the simplest, valid 




1 2 3 4 5 
Clearly stating all sources 
and assumptions of the cost 
effectiveness study 
1 2 3 4 5 
 
 
2. Which two factors would you rank as most important in terms of the usefulness of cost 
effectiveness studies for infection control decision making? (please mark  for the two factors) 
The quality of the clinical evidence that informs the cost effectiveness study 
The rigour of the methodology used to estimate cost effectiveness 
The length of time required to conduct the cost effectiveness study 
Making cost effectiveness studies easier to interpret by improving communication and using plain 
language 
Professional training in interpreting and evaluating cost effectiveness studies 
Considering equity effects of healthcare interventions in cost effectiveness studies 
Considering budget impact of healthcare interventions in cost effectiveness studies 
Considering clinical need of healthcare interventions in cost effectiveness studies 
Avoiding conflicts of interest (e.g. studies funded by pharmaceutical or medical device companies)  
Using the simplest, valid approach to measuring cost effectiveness (avoiding unnecessarily 
complex methods) 
Clearly stating all sources and assumptions of the cost effectiveness study 
 
 
3. Which two factors would you rank as least important in terms of the usefulness of cost 
effectiveness studies for infection control decision making? (please mark  for the two factors) 
The quality of the clinical evidence that informs the cost effectiveness study 
The rigour of the methodology used to estimate cost effectiveness 
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The length of time required to conduct the cost effectiveness study 
Making cost effectiveness studies easier to interpret by improving communication and using plain 
language 
Professional training in interpreting and evaluating cost effectiveness studies 
Considering equity effects of healthcare interventions in cost effectiveness studies 
Considering budget impact of healthcare interventions in cost effectiveness studies 
Considering clinical need of healthcare interventions in cost effectiveness studies 
Avoiding conflicts of interest (e.g. studies funded by pharmaceutical or medical device companies)  
Using the simplest, valid approach to measuring cost effectiveness (avoiding unnecessarily 
complex methods) 
Clearly stating all sources and assumptions of the cost effectiveness study 
4. Please rank the following in order of importance from 1 to 4 where 1 is most important to you
and 4 is least important to you
Making cost effectiveness studies easier to interpret by improving communication and using plain
language
Professional training in interpreting and evaluating cost effectiveness studies
Using the simplest, valid approach to measuring cost effectiveness (avoiding unnecessarily
complex methods)
Clearly stating all sources and assumptions of the cost effectiveness study
5. What factors do you think make cost effectiveness information more or less valuable?
6. How often do you use cost effectiveness information to make infection control decisions?
1 2 3 4 5 6
Never Very rarely Rarely Sometimes Often Very often
7. How often do you think you should use cost effectiveness information to make infection control
decisions?
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1 2 3 4 5 6
Never Very rarely Rarely Sometimes Often Very often
8. In general, how valuable do you think cost effectiveness information is for making infection
control decisions?
1 2 3 4 5 
Not at all valuable Somewhat valuable Moderately valuable Valuable Very valuable
9. In general, how useful do you think cost effectiveness information is for infection control decision
making?
1 2 3 4 5 
Not at all To some extent A moderate extent A large extent A very large extent
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Section 2: Timeliness and conflicts of interest  
10. Imagine a scenario where you have commissioned a health economist to produce an economic
evaluation to inform an infection control decision.
What do you think would be a reasonable time to complete the economic evaluation? 
_______________________________________________________ 
What do you think would be the minimal time the economic evaluation could be completed in? 
_______________________________________________________ 
What is the maximum time you would be willing to wait for the completion of the economic 
evaluation? 
_______________________________________________________ 
11. Health economists may have a number of different types of conflict of interest. Please rate how
important you think each type of conflict of interest is with respect to trusting the outcomes of
the research.









Health economist is 
employed by company that 
has a financial interest in 
the economic evaluation 
1 2 3 4 5 
Health economist has 
received funding by a 
company that has a 
financial interest to develop 
the economic evaluation 
1 2 3 4 5
Health economist 
previously received research 
funding by a company with 
a financial interest in the 
economic evaluation  
1 2 3 4 5 
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attendance at a conference 
was paid for by a company 
with a financial interest in 
the economic evaluation. 
























By agreeing to participate in this study, you are agreeing that you: 
have read and understood the information provided in the Information to Participants 
section. 
have had any questions answered to your satisfaction. 
agree to participate in this survey 
understand that once you have submitted your responses, these cannot be withdrawn. 
agree that research data collected for this study may be published or may be provided to 
other researchers 
Please read the statements above and tick below to give your consent to 
participate: 
I agree and give my consent 





None of the above 
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Please consider the following hypothetical scenario 
Imagine you are to provide feedback to the management of your hospital on whether the 
hospital should purchase a new piece of equipment. There is some evidence that the 
new piece of equipment will improve the health of patients.  
There is a significant cost to purchase, install, and learn how to use the new piece of 
equipment.  
To help you provide feedback you can choose one of two health economists who will 
conduct a study to evaluate the cost-effectiveness of the piece of equipment.  
You will be given comparisons of the two health economists in tables like the one 
below. You will be asked to select the economist that you would be more likely to 
choose. 
Economist A Economist B
Quality of clinical evidence Good Good 
Quality of economic 
modelling 
Good Poor
Length of time 12 months 6 months 
Communication Poor Good
Equity No consideration Mentioned 
Applicability Specifically applied to 
context 
Not applied to 
context 
Conflict of interest Employed by industry No conflict 
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Comparison 1(of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment?   
Economist A Economist B 
Quality of clinical 
evidence Fair Fair 
Quality of economic 
modelling Fair Fair
Length of time 6 months 12 months 
Communication Fair Poor
Equity Mentioned Thorough analysis 
Applicability Generally applied to context 
Specifically applied to 
context 
Conflict of interest Employed by industry Independent with industryfunding 
 
Economist A  
Economist B  
Comparison 2 (of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment?  
Economist A Economist B 
Quality of clinical evidence Good Fair 
Quality of economic modelling Good Fair
Length of time 6 months 6 months 
Communication Fair Fair
Equity No consideration Mentioned 
Applicability Not applied to context Generally appli
Conflict of interest Independent with industry funding Employed by in
Economist A  
Economist B  






Comparison 3 (of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
 Economist A Eco
Quality of clinical evidence Poor Poo
Quality of economic modelling Poor Poo
Length of time 1 month 12 m
Communication Good Poo
Equity Mentioned No 
Applicability Generally applied to context Not
Conflict of interest Independent with industry funding Emp
 
 
Economist A   
 






Comparison 4 (of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
 Economist A Economist B
Quality of clinical evidence Good Good 
Quality of economic modelling Fair Good 
Length of time 1 month 6 months 
Communication Poor Fair 
Equity Mentioned No considerati
Applicability Not applied to context Not applied to 
Conflict of interest No conflict Independent w
 
 
Economist A   
 
Economist B   
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Comparison 5 (of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
Economist A Economist B
Quality of clinical evidence Poor Good 
Quality of economic modelling Good Good
Length of time 12 months 1 month 
Communication Fair Good
Equity Thorough analysis Thorough ana
Applicability Generally applied to context Specifically ap
Conflict of interest No conflict Employed by 
Economist A  
Economist B  
 
Comparison 6 (of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
Economist A
Quality of clinical evidence Fair Poor 
Quality of economic modelling Poor Poor
Length of time 6 months 1 month 
Communication Good Good
Equity No consideration Mentioned 
Applicability Specifically applicable to context Generally appl
Conflict of interest No conflict Independent w
 
Economist A  
Economist B  
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Comparison 7(of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
 
 
 Economist A Economist B
Quality of clinical evidence Good Good 
Quality of economic modelling Poor Fair 
Length of time 6 months 1 month 
Communication Poor Poor 
Equity Thorough analysis Mentioned 
Applicability Generally applied to context Not applied to 
Conflict of interest Independent with industry funding No conflict 
 
 
Economist A   
 







Comparison 8 (of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
 
 Economist A Economist B 
Quality of clinical 
evidence Good Poor 
Quality of economic 
modelling Fair Good 
Length of time 12 months 12 months 
Communication Good Fair 
Equity No consideration Thorough analysis 
Applicability Generally applied to context 
Generally applied to 
context 
Conflict of interest No conflict No conflict 
 
 
Economist A   
 
Economist B   
 
Comparison 9 (of 10) 
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Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
 
 Economist A Economist B 
Quality of clinical 
evidence Fair Fair 
Quality of economic 
modelling Fair Fair 
Length of time 6 months 12 months 
Communication Fair Poor 
Equity Mentioned Thorough analysis 
Applicability Generally applied to context 
Specifically applied to 
context 
Conflict of interest Employed by industry Independent with industry funding 
 
 
Economist A   
 






Comparison 10 (of 10) 
Which health economist would you be more likely to choose to provide evidence on the 
cost-effectiveness of the new piece of equipment? 
 Economist A Economist B
Quality of clinical evidence Poor Fair 
Quality of economic modelling Good Poor 
Length of time 6 months 6 months 
Communication Poor Good 
Equity Mentioned No considerati
Applicability Specifically applied to context Specifically ap
Conflict of interest No conflict No conflict 
 
 
Economist A   
 
Economist B   
 
When making your choices beetween health economists did you find yourself focussing 
on one particular factor? If so, which one? 




















How often do you use cost-effectiveness information for healthcare decision-making? 
 
Never Seldom Sometimes Often Almost 
Always 
1 2 3 4 5 
 
 
How often do you think you should use cost-effectiveness information for healthcare 
decision-making? 
 
Never Seldom Sometimes Often Almost 
Always 
1 2 3 4 5 
 
 
In general, how valuable do you think cost-effectiveness information is for healthcare 
decision-making? 
 




Valuable Very Valuable 






Male   






What is your primary work setting? __________________________________ 
What is your country of residence?  __________________________________ 
How difficult did you find this questionnaire to complete? 
Very Easy Easy Neutral Difficult Very Difficult 
1 2 3 4 5 
Do you have any additional comments you would like to make about this research or the 
factors which influence your choice to use economic information? 
Thank you very much for taking the time to complete this survey. 
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APPENDIX D: INTERVIEW PROTOCOL 
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7.1.1.1 Interview Protocol  
7.1.1.2 Project: The influence of economic evaluation on healthcare policy and 






Participant Information Form signed:_______________  
I’d like to understand your experiences developing economic evaluations and using that knowledge to make 
changes in the healthcare system 
The interview should take half an hour, is that OK with your schedule? 
Did you receive the signed consent form? Do you have any questions regarding the form? 
[Obtain signed request form] 
Confirm OK with audio recording 
[Start audio recording] 
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Main question Additional questions
Can you describe your experience with economic evaluation
Q1. I would like you to think of an economic evaluation that you have worked on in the past couple of 
years. Preferably one that is now finished. 
Why did you start on that economic 
evaluation? 
Why were the sponsors interested  
How do you decide how broad a perspective you are going 
to take? 
What methods did you use?  
Trial-based/decision analytic? 
How do you determine the scope of an economic 
evaluation?  
How did you disseminate your research 
How was it communicated?
What was the response like? 
Was this economic evaluation 
characteristic of the types of economic 
evaluations that you do? 
If not how do others differ 
Would you say that the economic 
evaluation led to some change in the 
health system? 
If not 
Do you think it served another role? 
What do you think would need to change 
If yes 
In what way? 
Do you think it served another role? 
Are there cases where you would think it was not 
appropriate to do an economic evaluation? 
 
Q2. In what ways can the process of 
producing economic evaluations be 
improved? 
 
Q3. What do you think are the most 
important things you as a researcher can 
do to translate evidence from economic 
evaluation into practice? 
What do you think are the most important things your 
research institution can do to translate evidence from 
economic evaluation into practice? 
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Is there anything we have talked about so far that you wish to elaborate on or anything you have 





APPENDIX E: INTERVIEW TRANSCRIPTS 
(HE#, Health Economist; G=Interviewer) 
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HE9 interview – 16th December 2015 
  GM: I try to cover three questions in each of these interviews. First, go through a case 
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does its own thing. There’s still some oversight 
  GM: And I guess the bigger hospitals… 
  HE9: They still don’t have as much power. 
  GM: Now the last thing, and we have sort of touched on this. What can individual 
researchers, or even research institutions—say universities—can do to help the use of 
evidence from economic evaluation. 
  HE9: I think universities are struggling with that themselves. Innovation and translation is 
really the thing. And it’s one of the things that are earmarked for performance. I’ve had 
numerous discussions with actors up the chain about how they can evidence translated. 
You’ve got people have identified a gene or a gene fault and most times it doesn’t lead 
to anything but the odd one does lead to something. Melanoma treatment is the latest 
thing and there’s going to be something for MS hopefully one day. And nationally there 
was a big one; it was a drug for myeloid leukaemia. And it was one of the first drugs for 
leukaemia to get up – but it was developed at the start of the 60’s, but it didn’t get to 
market till 98 or something. Or it didn’t get to trial before 98 so a long time in 
development. I’ve heard the person who developed it say, well he’s the innovator he 
really translated it. He identified what the problem was and he identified what the 
therapy should be. And he generated that therapy. Now chronic myeloid leukaemia, the 
sufferers are typically older men. It’s the acute the lymphocity that tends to hit younger. 
He identified that as a major chromosomal disorder and here’s the drug that should 
counteract that because that mutagen generates an incomplete proteins. He identified 
the drug that shuts that protein down. Brilliant, should work. So that’s as far as he got. 
But he couldn’t get the drug to work so he went on to something else. He handed the 
project to a team of people and it took them 30 years, lots of monkeys involved, lots of 
dogs all sorts of things, bred very specifically to do this. The theory was right but he 
couldn’t get it to work, someone else came along, “oh, we’ll try it this way”. It was oral 
form instead of IV. The oral form worked but they still don’t know why. So they put it 
through clinical trials and then he came to me as a health economist what’s the 
evidence, what’s the cost‐effectiveness of it? How much can I charge for it? So I did the 
submission to NICE. So that’s a long story, but it takes all those steps. 
  GM: Do you see a distinction between the sort of research that was happening before… 
  HE9: The basic science? 
  GM: Yeah, the basic science. Is translation of basic science different to translation of 
cost‐effectiveness evidence? 
  HE9: The basic scientist will say “wow, this is fantastic. They’ve developed this and it’s 
translated into new line of chemotherapy. Well, no. It was a whole chain of events from 
the molecular stage to a pharmaceutical stage. Wow that’s fantastic. Then someone else 
translated the pharmaceutical into a clinical trial. So there’s a whole raft of translational 
issues and who gets credit for what. I think economists really miss out on that, because 
it’s the economist who makes the case to government to say this is good value for 
money. Here’s the evidence, here’s what it’s going to cost, here’s what it’s going to save, 
we are going to extrapolate that out for the country. Bam, is this worth funding? Is this 
worth the government subsidising. 
  GM: Would you say it was the last research component in the process? 
  HE9: I think that’s right. 
  GM: Those were my questions, but is there anything else that I forgot? 
  HE9: Back to your second question. About what can be done about economic 
evaluation? I’ve spoken about it as being fairly black and white. It’s either good value for 
money or it’s not. But in between there are some grey areas. Do you fund something if 
there is a good deal of uncertainty but it looks like if might be cost‐effective—there are 
longer term outcomes that aren’t clear because we haven’t done longitudinal stuff or 
follow‐up studies. Do we do some clinical trials and fund it or do we wait for that 
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evidence to come through. You can either fund it and wait for evidence or not fund it 
and wait for evidence. Unless you can say this is poor value for money no matter what 
and we’re never going to fund it. So there is four categories. Those middle two really 
need a lot more work they, those two categories we can really say, right, what are the 
key things we really need—simple survival, there will probably something else, rate of 
rehospitalisation, or some other measure of clinical benefit. It might be some parameter. 
So, what do we do? We know that there is some kind of benefit. If we fund it we know 
some people are going to benefit. There is some risk of benefit but we don’t know what 
those trade‐offs are. That in Australia is poorly done, It’s really poorly done. They’ll get 
something, go on an approve it or they’ll say they won’t don’t even go there. They’ll 
defer it—usually to wait for more evidence. That’s where risk‐sharing agreements come 
in. PBAC mostly used them for population risk—the biggest source of uncertainty. And 
then you get to value of information. Identify key parameters. 
GM: So if you think of value of information as almost its own type of economic. What are 
the challenges for translating value of information? 
HE9: Lots of challenges. There’s technical challenges—because you’ve got to develop the 
probabilistic sensitivity analysis. PBAC don’t like that. There are major barriers at that 
point. The government just don’t like PSAs. It doesn’t get used in the clinical setting. 
They say they want to know what are the key drivers of the model and that’s sensitivity 
analysis. That’s true, but I think you’ve got to do both. There’s technical barriers for the 
economist getting the model together and there’s barriers for the reader—the end 
user—to say “what does this all mean?” It’s got to be in a format and language so that 
they can understand 
